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1. Introduction 
1.1 Breast cancer 
1.1.1 Ethiology 
Over 1 million breast cancer cases occur worldwide every year (Ferlay et al., 2001) and it is 
now first among cancers affecting women. Men can also develop breast cancer, however 
the accounts to only 1% of all breast cancers (Olivotto et al., 2006). With 429 900 new 
cases in Europe, breast cancer consisted 13.5% of all cancer occurrences in 2006 (Ferlay 
et al., 2007). Increased risk for breast cancer development includes various factors which 
can be grouped as fallows: hormones and reproductive factors; diet and diet related factors; 
ionizing radiation; family history of breast cancer; benign breast disease. Some risk factors 
are particularly related to reproductive life in women such as early age of menarche, late 
age at first birth, lack of breast feeding and oral contraceptives. Among endogenous risk 
factor, genetic predisposition is responsible for about 5-10% of all breast cancer incidences. 
The most important genes identified in this context are inherited mutations in BRCA1 and 
BRCA2 genes (Eeles, 1999). BRCA1 mutations appear to be responsible for 45% of breast 
cancers in families with multiple cases of breast cancer and BRCA2 is responsible for 35% 
of familiar breast cancers (National Cancer Institute 2005d)1. Other risks factors are listed  
in Fig. 1.1. 
1.1.2 Classification 
Breast cancer in most cases refers to malignancies in women that arise from the terminal 
ductal-lobular units of epithelial tissue (Stewart and Kleinhaus, 2003). Breast cancers can 
be differentiated into two main groups: non-invasive (in situ) and invasive breast cancer. 
Breast cancer in situ refers to a cancer where proliferation of presumably malignant 
epithelial cells is confined to the mammary ducts and/or lobules. Invasive breast cancer is 
capable of invading distant tissues – metastasizing. In both groups lobular and ductal 
carcinomas are distinguished. The most frequent malignant lesion of the breast (75-80%) is 
invasive (infiltrating) ductal carcinoma (Fig.1.2.). About 20% of infiltrating ductal carcinomas 
(IDC) can be categorized into histomorphological subtypes: tubular, medullar, mucinous, 
                                                 
1
  http://www.son.wisc.edu/ce/programs/asynch/bccd/BrCa1/BreastMod1AddlResources.pdf 
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FEMALE BREAST CANCER
DIET AND DIET-RELATED FACTORS
Increased weight (postmenopause) ↑
Increased height ↑
Western diet ↑
High intake of fibre?↓
Alcohol↑
High intake of fresh fruit and vegatables↓
IONIZING 
RADIATION
at times of 
breast
development ↑
HORMONES AND 
REPRODUCTIVE FACTORS
Young age at menarche ↑
Regular, ovular menstrual cycle ↑
Older age at first full-term birth ↑
Oral contraceptives ↑
Infertility ↑
Lack of breast feeding ↑
FAMILY HISTORY OF BREAST CANCER ↑
including BRCA1, BRCA2, and p53
germline mutations
BENIGN BREAST DISEASE ↑
Including atypical ductal
hyperplasia
 
Fig. 1.1 Risk and protective factors for breast cancer development. Factors associated with 
an increased (↑) or decreased (↓) risk of breast cancer (modified from Stewart B.W, Kleihues 
P, World Cancer Report 2003, p. 190; IARC Press, Lyon). 
papillary, micropapillary, metaplastic. The remaining 80% do not belong to any of these 
specific tumor sub-classes and are thus called “Not Otherwise Specified” (NOS)  
(Yoder et al., 2007). 
1.1.3 Invasive ductal breast cancer – desmoplastic reaction 
Most invasive-ductal breast tumors develop a desmoplastic reaction, also termed scirrhous 
reaction. Desmoplastic response is a host mediated collagenous response and results from 
a complex interaction between the host and invading tumor cells. Desmoplastic regions 
consist of fibroblasts, inflammatory cells and vascular structures. This characteristic tumor 
appearance, often described as “lump”, can vary from a predominantly cellular form 
(fibroblasts/myofibroblasts) with little collagenous matrix to dense fibrous stroma with few 
stromal cells (Walker, 2001). The mechanism of desmoplasic reaction is not well 
understood and its role as prognostic marker for cancer is still disputed. 
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lobules
nipple
duct
fat
duct
lobules
invasive ductal
carcinoma
 
Fig. 1.2 Diagram of the breast; enlarged is a cross-section of an invasive ductal carcinoma 
(modified from Meuret, 1995. Mammakarzinom. 2nd ed. Georg Thieme Verlag, Stuttgart ). 
Generally, desmoplasia in epithelial cancers is considered as a tumor promoting factor. 
This was proven in a variety of experimental tumor models in which an impact of stromal 
microenvironment on various stages of tumorigenesis was shown (Elenbaas and Weinberg, 
2001). The work of Shao et al. indicated that the desmoplastic response in breast tumor 
carcinomas may be a substantial barrier to gene and immunotherapies (Shao et al., 2000). 
On the other hand, such a barrier may also prevent tumor invasion (Vaage, 1992; Lieubeau 
et al., 1994). Moreover, both carcinoma cells and stromal cells are known to secrete 
autocrine and paracrine factors which can be involved in growth stimulation or inhibition 
(Horgan et al., 1987; Osborne et al., 1989). Some authors report that the major initiator of 
tumor desmoplasia is the secretion of platelet-derived growth factor (PDGF) by breast 
carcinoma cells. Only tumor cells that secrete significant amounts of PDGF and at the same 
time lack expression of a PDGF receptor seem to exhibit a desmoplastic reaction (Shao et 
al., 2000). Moreover, tumor progression may also be affected by other paracrine factors 
Introduction  4 
 
released by stromal cells in the desmoplastic areas such as cytokines, ECM (Extracellular 
matrix) and ECM modulating molecules (Devalaraja and Richmond, 1999) as well as by 
direct cell-cell interactions between tumor and stromal cells such as fibroblasts (Steffen et 
al., 1998). 
1.2 Tumor heterogeneity 
1.2.1 Cellular interactions in solid tumors 
About 90% of human tumors arise as a consequence of genetic mutations in epithelial cells, 
leading to their abnormal proliferation. But these malignant cells are not isolated islands, 
they are surrounded by a peritumoral stroma comprised of diverse host cell types 
(immunocompetent cells, inflammatory cells, fibroblasts and endothelial cells) and 
extracellular matrix (ECM) (Hanahan and Weinberg, 2000). Tumor cells influence their 
microenvironment (Fig. 1.3) and for example induce a desmoplastic reaction as described 
earlier, and in turn the surrounding cells critically affect the multistep process  
of carcinogenesis and the malignant phenotype (van Roozendaal et al., 1995). 
Fibroblasts
Tumor cells
Immune cells
(e.g. monocytes/macrophages,
NK-cells, T-cells)
Endothelial cells
 
Fig. 1.3 Heterologous cellular interactions in solid tumors (Kunz-Schughart & Knuchel, Histol. 
Histopathol. 2002a, 17: 599-621). 
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1.2.2 Tumor-associated fibroblasts (TAF) 
There is increasing evidence that fibroblasts, the predominant stromal cell type in tumor 
desmoplasia, are involved in tumor progression and can no longer be considered as 
passive structural elements (Wernert, 1997; Elenbaas and Weinberg, 2001; Kunz-
Schughart and Knuechel, 2002a; Kunz-Schughart and Knuechel, 2002b). These fibroblasts 
differ phenotypically from the normal one. Hence, fibroblast contributing to the tumor stroma 
are termed reactive stroma, peritumoral fibroblasts, carcinoma-associated fibroblasts or, as 
in current thesis, tumor-derived/tumor-associated fibroblasts (TAF). At both, primary and 
metastatic sites of tumors, TAF are able to influence proliferation, differentiation and 
invasion of malignant cells (van den Hoff, 1991). Fibroblasts are an extremely 
heterogenous population of cells and also can give rise to different types of TAF (Schor  
et al., 1994; Gregoire and Lieubeau, 1995). 
Fibroblasts derived from breast carcinomas, as compared to those from normal breast 
tissue, show an altered, oncogenic and/or myofibroblastic phenotype. One special feature is 
the synthesis of intracellular α-smooth muscle actin (Brouty-Boye et al., 1991; Ronnov-
Jessen et al., 1996; Schurch, 1999). TAF can contain high levels of myofibroblasts, up to 
80% of the whole population (Heimdal et al., 2001). According to literature data, the 
presence of myofibroblast characteristics in the desmoplastic reaction of tumors is 
positively correlated with tumor invasiveness (De Wever and Mareel, 2002; De Wever et al., 
2008). TAF also differ in cell surface (integrins, cell adhesion molecules) and secretory 
(growth factors, cytokines/chemokines) protein expression (Kunz-Schughart and Knuechel, 
2002a) that act on the epithelial tumor cells and can promote tumor growth (Elenbaas and 
Weinberg, 2001). However, not only TAF from invasive cancers but also fibroblasts derived 
from benign prostatic hyperplasia may, in contrast to normal fibroblasts, show tumor 
promoting ability when admixed with nontumorigenic prostate epithelial cell line (Olumi  
et al., 1999). 
Several growth factor levels have been found to be elevated in such fibroblasts. Once 
secreted, growth factors can stimulate growth of tumor cells by paracrine signaling, induce 
autocrine loops or positively impact tumor angiogenesis. Examples of such growth factors 
expressed in stroma are the insulin like-growth-factors (IGF-I and IGF-II) which are 
mitogens for different cell types including fibroblasts and epithelial cells and therefore exert 
probably both auto- and paracrine effects on tumor growth. IGFs are expressed in stromal 
fibroblasts of breast cancers and the expression of IGF-II in particular correlates with tumor 
progression (Yee et al., 1989; Cullen et al., 1992). 
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Epithelial tumor cells express molecular mediators such as TGF-β which interact with the 
surrounding cells. In breast cancers expression of high level of TGF-β1 is positively 
correlated with disease progression (Gorsch et al., 1992). According to research performed 
by several groups, TGF-β1 can induce differentiation of cell-cycle arrested fibroblasts into 
myofibroblasts in culture and may thus relate to the of myofibroblasts presence  
in desmoplastic tumors which positively correlates with tumors invasiveness (Ronnov-
Jessen and Petersen, 1993; Vaughan et al., 2000). 
1.2.3 Tumor-associated macrophages (TAM) 
Many solid tumors are characterized by the presence of leukocytic infiltrate. Tumor-
associated macrophages (TAM) are a major component of the infiltrate in tumors. They 
primarily arise as a result of abnormal maturation of monocytes (MO) migrated into tumor 
tissues from the blood stream (van Ravenswaay C et al., 1992). TAM were first investigated 
for their role in antitumor response, later studies showed that cancer induce functional 
abnormalities leading to an immature macrophage phenotype that can promote tumor 
growth (Mantovani et al., 1992; Sunderkotter et al., 1994). Those findings revealed a dual 
role of macrophages (MAC) in cancer. Macrophages, after their activation by antibodies, 
LPS or IFN-γ can mediate reduction of tumor growth by non-specific anti-tumor cytotoxic 
mechanisms (direct cytotoxicity) or induction of specific cell lytic effects (indirect 
cytotoxicity) (Grabbe et al., 1994; Blachere et al., 1997). Activated MAC can release 
reactive oxygen intermediates (ROIs) (Young and Hardy, 1995), cytokines (Jones and 
Millar, 1989; Weiser et al., 1991) and metalloproteinases (Gorrin-Rivas et al., 2000), which 
can take part in antitumor response. On the other hand, TAM have been shown to play a 
key role in tumor progression by their ability to producing of various factors and employing 
different mechanisms as shown below in Tab. 1.1 (al-Sarireh and Eremin, 2000). 
Similarly to dual role of MAC/TAM in cancer, there are conflicting data on the relevance  
of extensive TAM infiltration in cancer progression. The presence of TAM infiltration 
correlates with poor prognosis in carcinomas of the breast, cervix and bladder (Bingle et al., 
2002). The observations in brain, prostate and lung tumors, however, are contradictory 
(Bingle et al., 2002). Thus may be due to the fact that TAM can inhibit tumor growth and 
destroy neoplastic cells, but also support tumor development, metastasis and angiogenesis 
(Brigati et al., 2002; Tsung et al., 2002; Schoppmann et al., 2002). Which of these functions 
is dominant may depend on the differentiation status of TAM which is affected by the tumor 
cells, their stroma and environment. As reported by Nesbit et al., tumor tissue expressing 
high level of CCL2 was extensively infiltrated by MO and the tumor mass was eliminated. 
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Tumor tissue expressing low level of CCL2, were moderately infiltrated by MO and these 
tumors showed pronounced angiogenesis and rapid tumor growth (Nesbit et al., 2001). 
These data demonstrate the contradictory role of TAM infiltrates in tumors. 
Tab. 1.1 TAM and tumor progression (Al-Sarireh & Eremin, J.R.Coll.Surg. Edinb. 2000, 45: 1-
16) 
Mechanism Mediator(s) 
Enhanced Growth Growth factors (EGF, PDGF, TGF-β) 
 Cytokines (IL-6, IL-1, TNF-α) 
 L-arginine derived polyamine 
Enhanced Angiogenesis Through production of various cytokines 
(GM-CSF, TGF-α, TGF-β, IL-1, IL-6, IL-8) 
and prostanoids 
 Procoagulant activity 
Invasion and Dissemination  Cytokines (TNF-α, IL-1) 
 Lytic enzymes (metaloproteinases and 
plasminogen activator) 
Immunosuppression Prostanoids (PGE2) 
 Cytokines (IL-10)  
and other mediators (TGF-β) 
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1.3 Classification of MO subpopulations 
Monocytes (MO) are part of the human mononuclear phagocyte system and constitute 
three to eight percent of the leukocyte in the human blood. They play a role in processes 
such as antigen presentation, phagocytosis and inflammation. They secrete different 
molecules, including chemokines that are important in infectious processes and malignancy 
(Nathan, 1987; Ziegler-Heitbrock, 1989). MO derive from myelomonocytic stem cells  
in bone marrow which give rise to monoblasts, that develop into MO. MO circulate in the 
blood stream for about 1-3 days. Then they migrate into the various tissues and mature into 
different types of MAC depending on their location. MO are also assumed the primary and 
major leukocyte infiltrate in tumor tissue and the main source of TAM. 
The first attempts to classify MO focused on their differences in size and density. Using 
gradient centrifugation and elutriation two main subsets of MO were distinguished which 
differed phenotypically and functionally: a major subpopulation of “regular MO” and a minor 
one of “intermediate MO”. The smaller and denser “regular MO” produced fewer reactive 
oxygen intermediates, exhibited higher antigen presenting capacity and proliferated with 
lower activity than “intermediate MO” (Yasaka et al., 1981; Turpin et al., 1986; Inamura  
et al., 1990). Via rosetting with antibody-coated erythrocytes, Fcγ receptor positive (FcγR+) 
and negative (FcγR-) monocytes could be separated and the FcγR- MO were found to have 
a greater antigen-presenting capacity (Zembala et al., 1984; Szabo et al., 1990). 
Subpopulations were also defined on the basis of adherence to fibronectin (FN)-coated 
surfaces. Fn adherent cells constitute about 20% of all monocytes (Brown et al., 1989). The 
Fn-adherent MO were found to express 20-fold more peroxidase activity as compared  
to the non-bound MO (Owen et al., 1992). It is noted, however, that the selection methods 
mentioned did not lead to pure MO population and the accuracy of analyses was affected 
by contamination of other cell types. 
A more accurate phenotypic analysis of MO is possible by the use of flow cytometry and 
employing two- or multi-color immunofluorescence. Ziegler-Heitbrock defined blood MO 
based on the expression of CD14 antigen (major receptor for bacterial lipopolisacharide) 
and CD16 antigen (Fcγ receptor type III) expression. This approach revealed that about 
90% of all MO strongly express CD14 and are at the same time CD16-negative 
(CD14++CD16-). A minor population of MO co-expresses CD14+ and CD16+ at low level 
(Ziegler-Heitbrock, 1996). The same author also showed that the CD14+CD16+ 
subpopulation can be described as pro-inflammatory. It produces pro-inflammatory 
cytokines such as TNF, IL-1 and IL-6 but not anti-inflammatory IL-10. CD14+CD16+ cells 
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increase in number in diseases like sepsis (Fingerle et al., 1993), HIV+ and AIDS (Dunne  
et al., 1996; Zembala et al., 1997), which are characterized by high cytokine production 
(Ziegler-Heitbrock, 1996). Using the CD14/CD16 staining and additional markers Rothe and 
coworkers defined six different subsets of MO (CD14++CD16-, CD14+CD16-, CD14++CD16+, 
CD14+CD16-CD33dim, CD14+CD16-CD33high, CD14++CD16+CD56+) (Rothe et al., 1996). The 
use of CD markers showed that the heterogeneity of blood MO is enormous. It is highly 
relevant to elucidate the functional and clinical significance of the different MO subsets  
in health and disease and their potential to differentiate into a tumor-promoting TAM 
phenotype. 
1.4 Proinflammatory cytokines 
1.4.1 The family of chemokines 
Chemokines are small, low molecular weight (8-11 kDa) proinflammatory cytokines, which 
are characterized by their ability to induce migration and activation of specific leukocyte 
subsets (Kunkel, 1985; Baggiolini and Dahinden, 1994 ;Hedrick and Zlotnik, 1996). They 
play a role in inflammatory diseases (Murdoch and Finn, 2000), can act as autocrine and 
paracrine growth factors, induce angiogenesis, regulate metastasis, and influence tumor 
rejection (Wang et al., 1998). The large family of chemokines, containing nearly  
50 members, is divided into subfamilies based on their structural motifs. Most chemokines 
contain conserved cysteines residues, which are important for their secondary structure. 
Based on the spacing of the first two cystein residues they are classified into four groups: 
CXC (α), CC (β), C (γ) and CX3C (δ) where C stands for cysteine and X for any other amino 
acid (Rollins, 1997; Baggiolini, 1998). Considering their activities, chemokines can be 
divided into homeostatic chemokines which regulate traffic and activation of leukocytes, and 
the so-called inflammatory chemokines which trigger functional immune response (Mellado 
et al., 2001a). 
Chemokines can be produced by almost every nucleated cell type under appropriate 
conditions (Gale and McColl, 1999). Most chemokines are expressed in response  
to stimulus, but some are constitutively expressed in a tissue-specific manner and may also 
depend on the origin of cells. The BRAK chemokine is, for example, constitutively 
expressed at high levels in squamous epithelium, but require a stimulus to be expressed by 
inflammatory cells and certain cancers (Frederick et al., 2000). The most important ones 
shown to affect monocyte migration are CCL2, CCL3, CCL5, CCL4, which belong to the CC 
group of chemokines and signal via binding to so-called CCR receptors (see Tab. 1.2). 
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Tab. 1.2 The chemokine receptor family (modified from Murphy, Pharmacol. Rev. 2002, 54: 
227-229) 
Name Main Agonists Main Functions 
CR subgroup   
 XCR1 XCL1-2 T cell trafficking 
CCR subgroup   
 CCR1 CCL3, CCL5, CCL7, 
CCL8, CCL13-16, CCL23 
T cell and monocyte migration; 
innate and adaptive immunity; 
inflammation 
 CCR2 CCL2, CCL7, CCL8, 
CCL13 
T cell and monocyte migration; 
innate and adaptive immunity; Th1 
inflammation 
 CCR3 CCL5, CCL7, CCL8, 
CCL11, CCL13, CCL15, 
CCL24, CCL26 
Eosinophile, basophile, and T cell 
migration; allergic inflammation 
 CCR4 CCL17, CCL22 T cell and monocyte migration; 
allergic inflammation 
 CCR5 CCL3, CCL4, CCL5, 
CCL8, CCL14 
T cell and monocyte migration; 
innate and adaptive immunity; HIV 
infection 
 CCR6 CCL20 Dendritic cell migration 
 CCR7 CCL19, CCL21 T cell and dendritic cell migration; 
lymphoid development; primary 
immune response 
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 CCR8 CCL1, CCL4, CCL17 T cell trafficking 
 CCR9 CCL25 T cell homing to gut 
 CCR10 CCL26-28 T cell homing to skin 
CXCR subgroup   
 CXCR1 CXCL8 Neutrophile migration; innate 
immunity; acute inflammation 
 CXCR2 CXCL1-3, CXCL5-8 Neutrophile migration; innate 
immunity; acute inflammation; 
angiogenesis 
 CXCR3 CXCL9-11 T cell migration; adaptive immunity; 
Th1 inflammation 
 CXCR4 CXCL12 B cell lymphopoiesis; bone marrow 
myelopoiesis; central nervous 
system and vascular development; 
HIV infection 
 CXCR5 CXCL13 B cell trafficking; lymphoid 
development 
 CXCR6 CXCL16 T cell migration 
CX3CR subgroup   
 CX3CR1 CX3CL1 T cell and NK cell trafficking and 
adhesion; innate and adaptive 
immunity; Th1 inflammation 
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1.4.2 Chemokine receptors and their signaling pathways 
All chemokine receptors belong to the seven-transmembrane G protein-coupled receptor 
(GPCR) family. This receptor family contains a single polypeptide chain with  
an extracellular and a cytoplasmic region. The extracellular region is composed of the  
N-terminus and three extracellular loops, which bind the chemokine ligand. The intracellular 
region of receptor consists of three loops and C-terminus, which is responsible for signal 
transduction (Murphy, 1994). The chemokine receptors can also be grouped into four 
families: CR, CCR, CXCR and CX3CR, which interacts with the respective chemokines 
subfamilies C, CC, CXC and CX3C (Murphy et al., 2000). Receptors which belong to these 
four subfamilies are listed in Tab. 1.2. 
Chemokine receptors show a promiscuous behavior. As summarized in Tab. 1.2, many 
chemokine receptors bind more than one chemokine with varying affinities. CCR1, for 
example, bind with high affinity CCL3 (MIP-1α), CCL5 (RANTES), CCL7 (MCP-3), CCL8 
(MCP-2), CCL14 (HCC-1), CCL15 (Lkn-1) and CCL23 (MPIF-1) and with low affinity CCL4 
(MIP-1β) and CCL2 (MCP-1). Moreover, individual chemokines act as ligand for different 
receptors. MCP-3, for example, acts as a ligand for CCR1, CCR2, CCR3 and CCR5 
receptors (Murphy et al., 2000; Chou et al., 2002). 
Chemokine signaling involves the activation of a G-protein pathway. Interaction  
of a chemokine with its receptor leads to exchange of GDP for GTP and the dissociation  
of the α-subunit from the βγ-subunit. Dissociated subunits are able to activate several 
intracellular signaling pathways including the cAMP/protein kinase A pathway, the mitogen-
activated protein kinases (MAPK) pathway, the phosphatidylinositol/calcium/protein kinase 
C pathway and the c-Jun N-terminal kinases (JNK) pathway (Hamm, 1998; Lefkowitz, 1998; 
Iacovelli et al., 1999). The majority of the responses to chemokines are inhibited by 
pertussis toxin (PTX), due to the involvement of Gi proteins in signal transduction which are 
affected by PTX (Mellado et al., 1998; Rodriguez-Frade et al., 1999b). However, several  
G-protein-independent pathways can be also activated as e.g. JAK/STAT (Janus 
kinase/signal transducer and activator of transcription) cascade (Mellado et al., 1998; 
Williams, 1999). 
The JAK/STAT cascade is activated as result of the chemokine receptor homo- or hetero-
dimerization (Molino et al., 2000) (Fig. 1.4). This process was first demonstrated for CCR2, 
receptor for CCL2 (Rodriguez-Frade et al., 1999a). Today, it is well established that many 
chemokine receptors, if not all, must undergo a process of dimerization to become activated 
(Rodriguez-Frade et al., 1999a; Rodriguez-Frade et al., 2001; Mellado et al., 2001a; 
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Mellado et al., 2001b). A scheme of the chemokine receptor signaling pathways is given  
in Fig. 1.4. 
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Fig. 1.4 Schematic model of signaling pathways activated following chemokine binding to 
receptors. The figure shows some of the molecules involved in these pathways and the 
effects on cells. JAK: Janus-Kinase; STAT: Signal Transducer and Activator of Transcription; 
MAPK: MAP-Kinase; LMWG: Low Molecular Weight G-proteins; PLC: Phospholipase C; PKC: 
Proteinkinase C; PI3K: Phosphatidylinositol-3-Kinase; GRK: G-protein-coupled Receptor 
Kinases; PTX: Pertusis toxin (modified from M. Mellado et al. Annu. Rev. Immunol. 2001, 19: 
397-421). 
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1.4.3 CCL2 as a member of chemokine family 
CCL2, also known as monocyte chemoattractant protein -1 (MCP-1), belongs to the  
CC subfamily of inflammatory chemokines (Bacon et al., 2002). According to its biological 
role, it belongs to the group of inflammatory chemokines. Although it was first identified  
in 1989 as a substance secreted by malignant cells, that promotes monocyte migration 
(Yoshimura et al., 1989; Van Damme et al., 1989), it is also produced by non-malignant cell 
types. In vitro, constitutive secretion of human CCL2 has been reported for several solid 
tumor cell lines (Bokoch, 1995; Mellado et al., 1998), fibroblasts (Sanchez-Madrid and del 
Pozo, 1999) and monocytic human cell lines (Mellado et al., 2001a). It can, however, also 
be produced by endothelial cells following stimulation by cytokines, viruses, endotoxins and 
other substances like phorbol esters or lipopolisacharide (Proost et al., 1998). 
CCL2 induces cellular migration by binding to and activating the specific CC chemokine 
family receptor CCR2. The CCR2A/2B receptor exists in two isoforms named A and B. The 
isoforms are alternatively spliced variants of a single receptor gene that differ only in the 
sequence of the cytosolic carboxyl-terminal tail. The CCR2B isoform seems to be 
predominant one (Charo et al., 1994; Wong et al., 1997). CCR2A/2B is expressed on the 
surface of monocytes, activated memory T cells, B cells and basophilees (Frade et al., 
1997; Rabin et al., 1999). CCR2A/B is important in inflammation and host defense 
mechanism (Kuziel et al., 1997; Boring et al., 1997; Gonzalo et al., 1998). In addition to 
CCL2, CCR2A/2B can be activated by other inflammatory/inducible ligands such as CCL7  
(MCP-3), CCL8 (MCP-2), CCL13 (MCP-4) (Charo et al., 1994; Gong et al., 1997). 
CCL2 particularly attracts MO as originally described by Matsushima et al. (Matsushima  
et al., 1989). However, it can also induce migration of other cell types such as activated 
CD4 positive and CD8 positive memory T-cells, lymphocytes or NK cells (Leonard and 
Yoshimura, 1990; Carr et al., 1994). CCL2 plays a role in several physiological and 
pathophysiological states where MO/MAC infiltration and/or their activation is an important 
phenomenon. Among them are cancers, inflammatory heart disease, asthma, rheumatoidal 
arthritis, inflammatory skin diseases, bronchial infections, liver diseases and sepsis (Rollins 
and Sunday, 1991; Strieter et al., 1994; Baggiolini and Dahinden, 1994; Bossink et al., 
1995; Schroder et al., 1996). 
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1.5 Objective 
In ductal breast carcinomas a high macrophage content is correlated with poor prognosis 
and clinical outcome (Leek et al., 1996). These TAM originate from blood MO that have 
migrated into tumor tissue where they undergo abnormal differentiation and/or maturation. 
Little is known about the impact of desmoplastic fibroblast on these processes. Previous 
studies performed in our laboratory have shown that the proportion of MO migrating into 
spheroids of breast tumor-derived fibroblasts is significantly higher than in spheroids from 
normal skin and breast fibroblasts (Silzle et al., 2003). The recorded data imply the 
existence of a particular subpopulation of 10 to 15% in the blood MO pool which is capable 
to infiltrate spheroids of tumor-derived fibroblasts. Furthermore, it was documented that MO 
to fibroblasts ratio in co-cultures of normal and tumor-derived fibroblasts is correlated with 
the CCL2 release. Neutralization of endogenous CCL2 in conditioned media from breast 
tumor derived fibroblast spheroids, however, led to a pronounced reduction of MO migration 
only in a Boyden-Chamber assay, while the same antibody was inefficient in 3-D culture. 
This observation could result from: 
• insufficient distribution/penetration of the antibody in the spheroids 
• high accumulation of CCL2 within the spheroid that cannot be blocked with the 
antibody concentration applied 
• a CCL2 signaling pathway that does not play a significant role in MO migration into  
3-D fibroblast cultures 
With this background, the aim of the present thesis was: 
1. to verify the relevance of paracrine factors and in particular of CCL2/CCR2 signaling 
for MO migration into spheroids of fibroblasts and tumor cells of breast tumor origin. 
2. to identify and/or characterize the migrating blood MO subpopulation. 
In order to achieve these goals a three-dimensional (3-D) cell co-culture model under well 
defined conditions was applied, according to the one used by T. Silzle et al. (Silzle et al., 
2003). The model allows to mimic and investigate interactions of fibroblasts and tumor cells, 
respectively, with MO in vitro. 
MO migration into spheroids of breast-tumor derived fibroblast and also of defined breast 
carcinoma cell lines (MCF-7, T47D, Hs578T, BT549, BT474) was investigated and CCL2 
secretion was analyzed.  
The different experimental approaches to study the phenomenon of MO migration into 
fibroblastic tumor regions included: wash-out and addition of chemokines to modulate the 
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co-cultures’ milieu; application of siRNA; preincubation of MO with toxins and blocking 
antibodies. 
For studying the migratory activity of MO subpopulations, blood MO were stained for 
defined surface antigens and subpopulations were isolated using fluorescence-activated 
cell sorting (FACS) prior to spheroid exposure. Finally, gene expression profiles of migrated 
vs. non-migrated MO were compared using cDNA array analyses. 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Cell lines and primary cells 
2.1.1.1 Human breast cancer cell lines 
Five different breast cancer lines were used in this study. Cell lines Hs578, MCF-7 and 
BT549 were purchased from the ATCC, cell line T47D was from the ECACC and BT474 
was from the Tumorbank Heidelberg. All cell lines were free from mycoplasm as routinely 
verified by luminescence based mycoplasma test systems (Myco Alert Mycoplasma 
Detection Kit, Cambrex). 
 
T47D (Keydar et al., 1979; Sommers et al., 1994) 
This cell line was isolated from a pleural effusion obtained from a 54-year-old female patient 
with breast infiltrating ductal carcinoma.  
Hypertetraploid, ER+, PR+ 
In vitro invasion: + 
 
Hs578 (Hackett et al., 1977; Sennerstam and Auer, 1993; Sommers et al., 1994)  
Cell line derived from a carcinoma of the breast obtained from a mammary gland of a 74-
year-old female patient (Hackett et al., 1977). This line had a mixed polygonal morphology 
initially, but a stellate cell type was selected during passageing and cloning. Cells are 
tumorigenic in immunosuppressed mice. 
Hyperdiploid, ER-, PR- 
In vitro invasion: +++ 
 
MCF-7 (Sugarman et al., 1985; Sommers et al., 1994) 
The cell line is originated from malignant mammary gland tissue of a 69-year-old female 
patient with a differentiated, infiltrating ductal carcinoma. 
Hypertriploid to hypertetraploid, ER+, PR+ 
In vitro invasion: + 
 
BT549 (Smith et al., 1985;Sommers et al., 1994; Katayose et al., 1997) 
This cell line was isolated from malignant mammary gland tissue of a 72-year-old female 
patient with a papillary, invasive ductal tumor which had metastasized into regional lymph 
nodes.  
Hyperdiploid, ER-, PR- 
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In vitro invasion: +++ 
 
BT474 (Lasfargues et al., 1978; Sommers et al., 1994) 
The cell line was originated from malignant mammary gland tissue of a 60-year-old female 
patient, with a solid, invasive ductal carcinoma. Cells are tumorigenic in athymic mice. 
Hypertetraploid, ER+, PR+ 
In vitro invasion: + 
2.1.1.2 Primary cells 
Fibroblasts: 
VF1 – normal foreskin from child 
PF27T – invasive ductal adenomatous carcinoma of mammary gland in stage G2 
PF37T – invasive ductal adenomatous carcinoma of mammary gland in stage G2 
PF53T – invasive ductal adenomatous carcinoma of mammary gland in stage G2 
 
Monocytes: 
Peripheral-blood mononuclear cells (MNC) were obtained by leukopheresis of healthy 
donors. Monocytes (MO) were isolated from MNC by counter current centrifugal elutriation. 
2.1.2 Media, buffers and supplements 
2.1.2.1 Media and supplements 
Accutase PAA Laboratories GmbH, Pasching, Austria 
Amphotericin B PAA Laboratories GmbH, Pasching, Austria 
Collagenase III PAN Biotech GmbH, Aidenbach, Germany 
D-(+)-Glucose  (45% in tissue culture grade 
                                                              water) 
Sigma-Aldrich CHEMIE GmbH, Steinheim, 
Germany 
DMEM PAN Biotech GmbH, Aidenbach, Germany 
FCS PAN Biotech GmbH, Aidenbach, Germany 
Opti-MEM I Reduced Serum Medium with 
                                                GlutaMAX I 
Invitrogen GmbH, Karlsrue, Germany 
Penicillin/Streptomycin PAN Biotech GmbH, Aidenbach, Germany 
RPMI-1640 PAN Biotech GmbH, Aidenbach, Germany 
Trypsin/EDTA PAN Biotech GmbH, Aidenbach, Germany 
 
Freezing medium for MO 70% RPMI, 20% FCS, 10% DMSO 
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Medium for primary fibroblast culturing 80% DMEM, 20% FCS, 25 mM glucose, 100 U/ml 
penicillin, 100 µg/ml streptomycin, 
25 µg/ml amphotericin B 
Standard freezing medium 90% FCS, 10% DMSO 
Standard medium 90% DMEM, 10% FCS, 100 U/ml penicillin,  
100 µg/ml streptomycin 
2.1.2.2 Buffers and reagents for cell culturing and flow cytometry 
Blocking/Wash Buffer used for FC PBS pH 7,2-7,4 
1% FCS 
CASYton (dilution liquid for cell cultures)  Schärfe System GmbH, Reutlingen, 
Germany 
DMSO Merck, Darmstadt, Germany 
PBS PAN Biotech GmbH, Aidenbach, Germany 
2.1.2.3 Buffers and reagents for immunohistochemistry 
DAB Chromogen DAKO Cytomation, Glostrup, Denmark 
Diluent buffer DAKO Cytomation, Glostrup, Denmark 
Entellan Merck, Darmstadt, Germany 
2.1.2.4 Reverse Transcription PCR buffers and reagents 
Buffer M-MuLV RT Fermentas, St. Leon-Rot, Germany 
DEPC-treated Water (H2ODEPC) Fermentas, St. Leon-Rot, Germany 
dNTP Mix Invitrogen, Friesoythe, Germany 
DTT Invitrogen, Friesoythe, Germany 
Random Hexamer Primer Fermentas, St. Leon-Rot, Germany 
ReverAid M-MuLV Reverse Transcriptase Fermentas, St. Leon-Rot, Germany 
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2.1.3 Antibodies 
Tab. 2.1 Primary antibodies applied in flow cytometry and immunohistochemistry 
Antibody Origin Clone Conjugate Distributor 
anti-human CD90 mouse AS02 FITC Dianova GmbH, Hamburg, 
Germany 
anti-human CD14 mouse TüK 4 PE/Cy5 Immunotools, Friesoythe, 
Germany 
anti-human CD16 mouse LNK16 PE Immunotools, Friesoythe, 
Germany 
anti-human CD11a mouse MEM-25 - Immunotools, Friesoythe, 
Germany 
anti-human CD11b mouse MEM-174 - Immunotools, Friesoythe, 
Germany 
anti-human CD49e mouse SAM-1 FITC Acries Antibodies GmbH, 
Hiddenhausen, Germany 
anti-human CD45 mouse HI30 APC Caltag Laboratories 
GmbH, Hamburg, 
Germany 
anti-human CD45 mouse 2B11+PD7/26 - DAKO, Glostrup, Denmark 
anti-human CKpan mouse KL1 - Immunotech, Marseille, 
France 
anti-human CD31 mouse JC/70A - DAKO, Glostrup, Denmark 
anti-human α-SML mouse asm-1 - Dianova GmbH, Hamburg, 
Germany 
anti-human DOC-3 mouse - - kindly provided by Prof. Dr. 
Matthias Mack, Inner 
Medicine II, University of 
Regensburg, Germany 
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Tab. 2.2 Isotype control and secondary antibodies applied in flow 
Antibody Origin Clone Conjugate Distributor 
Isotypes     
IgG1 mouse 203 - Immunotools, Friesoythe, 
Germany 
IgG2 mouse 713 - Immunotools, Friesoythe, 
Germany 
Secondary Ab     
goat-anti-mouse goat polyclonal PE DAKO GmbH, Hamburg, 
Germany 
goat-anti-mouse goat polyclonal FITC Immunotools, Friesoythe, 
Germany 
2.1.4 Nucleotides 
2.1.4.1 siRNA constructs 
Negative Control siRNA Alexa Fluor 488 Qiagen, Hilden, Germany 
Self-designed siRNAs IBA GmbH Göttingen, Germany 
Silencer Validated siRNA CCL2 
(sequence not available) 
Ambion/Applied Biosystems, Darmstadt, 
Germany 
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Tab. 2.3 Sequences of siRNA constructs for MCP-1 gene silencing 
siRNA construct Sequence 
Alexa Fluor 488 
(negative control) 
5’ UUC UCC GAA CGU GUC ACG UdT dT 3’--
AlexaFluor488 
3’ ACG UGA CAC GUU CGG AGA AdT dT 5’ 
1 ds siRNA 
(self-designed) 
5’       GGG CUC GCU CAG CCA GAU GCA TT 3’ 
3’ TT CCC GAG CGA GUC GGU CUA CGU       5’ 
2 ds siRNA 
(self-designed) 
5’       GUG GUC CCA AAG AAG CUG UGA TT 3’ 
5’ TT CAC CAG GGU UUCUUC GAC ACU         5’ 
2 ds siRNA (self-designed) 5’ GGG CUC GCU CAG CCA GAU GCA TT 3’ 
2 se siRNA (self-designed) 5’ GUG GUC CCA AAG AAG CUG UGA TT 3’ 
2.1.4.2 PCR primers for real-time PCR 
CCL2 Real Time PCR primers  
(Muhlbauer et al., 2003) 
Metabion, Martinsried, Germany 
Housekeeping Gene 18S Real Time 
PCR primers 
Metabion, Martinsried, Germany 
Tab. 2.4 Sequences of primers for real-time (RT) PCR 
Primer Sequence 
CCL2 fw 5’ GCG GAG CTA TAG AAG AAT CAC 3’ 
CCL2 rev 5’ TTG GGT TGT GGA GTG AGT GT 3’ 
18S fw 5’ ACC GAT TGG ATG GTT TAG TGA G 3’ 
18S rev 5’ CCT ACG GAA ACC TTG TTA CGA C 3’ 
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2.1.5 KITS for RNA isolation, real-time PCR, oligonucleotide array 
Agilent Low RNA input Linear Amplification 
                                                                Kit 
Agilent Technologies, Böblingen, Germany 
One-Color Microarray-Based Gene 
                       Expression Analysis 
Agilent Technologies, Böblingen, Germany 
QuantiTect SYBR Green PCR Kit Qiagen, Hilden, Germany 
RNeasy Protect Mini Kit Qiagen, Hilden, Germany 
2.1.6 KITS for ELISA and immunohistochemistry 
Human CCL2/MCP-1 Immunoassay R & D Systems GmbH, Wiesbaden-
Nordenstadt, Germany 
StreptAB – Complex/HRP- Duett 
                              (Mouse/Rabbit) 
DAKO GmbH, Hamburg, Germany 
2.1.7 Reagents and chemicals 
2.1.7.1 Basic chemicals and reagents 
Acetone (100%) Acros Organics, New Jersey, USA 
Agarose (for Routine Use) Sigma-Aldrich CHEMIE GmbH, Hamburg, 
Germany 
BSA  Biomol GmbH, Hamburg, Germany 
Chloroform Carl Roth, Karlsruhe, Germany 
Ethanol Merck, Darmstadt, Germany 
Hydrogen peroxide  Merck, Darmstadt, Germany 
Methanol Merck, Darmstadt, Germany 
Oligofectamine Invitrogen, Friesoythe, Germany 
2-Propanol Merck, Darmstadt, Germany 
RNase AWAY Molecular BioProducts, San Diego, USA 
Saint -Mix Synvolux Therapeutics B.V., Groningen, 
Holland  
TRIzol Reagent Invitrogen, Friesoythe, Germany 
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2.1.7.1.1 Toxins and chemokines 
Cholera Toxin Biomol GmbH, Hamburg, Germany 
Cholera Toxin B-Subunit Biomol GmbH, Hamburg, Germany 
Pertussis Toxin CALBIOCHEM, Nottingham, UK 
Pertussis Toxin B-Oligomer CALBIOCHEM, Nottingham, UK 
rhMCP-1 Immunotools 
2.1.8 Consumables 
Cell culture flasks T25 (100 ml) BD Falcon, Heidelberg, Germany 
Cell culture flasks T75 (250 ml) BD Falcon, Heidelberg, Germany 
Cell culture flasks T175 (600 ml) BD Falcon, Heidelberg, Germany 
Cell strainer 70 µm pores BD Falcon, Heidelberg, Germany 
CRYO.S 2 ml Greiner, Solingen, Germany 
Disposable plastic pipettes 10 ml Bibby Sterilin, Staffordshire, UK 
Disposable scalpels NO. 10 PFM AG, Köln, Germany 
Eppendorf tubes 1.5 ml Eppendorf, Hamburg, Germany 
Extra Volume Tip 100-1300 µl Starlab GmbH, Ahrensberg, Germany 
FACS tubes 5 ml BD Falcon, Heidelberg, Germany 
Glass Pasteur pipettes 230 mm VWR international, Darmstadt, Germany 
Light Cycler Capillaries 20 µl Roche Diagnostics, Manheim, Germany 
Latex exam gloves Kimberly-Clark, Roswell, USA 
Microscope slides for Paraffin-IH R. Langenbrinck, Teningen, Germany 
Microtest tissue culture plates, 96 well BD Falcon, Heidelberg, Germany 
Needles 0.9x40 mm Becton Dickinson S.A., Fraga, Spain 
Nitrile exam gloves Semperit Technische Produkte, Vienna, 
Austria 
Petri dishes 94/16 ml Greiner, Solingen, Germany 
Pipette tips 1000 µl Greiner, Solingen, Germany 
Pipette tips 200 µl Greiner, Solingen, Germany 
Pipette tips 10 µl Greiner, Solingen, Germany 
Pipette tips PD sterile 2.5 ml Brand, Wertheim, Germany 
PP test tubes 15 ml Greiner, Solingen, Germany 
PP test tubes 50 ml Greiner, Solingen, Germany 
SafeSeal tips 1000 µl Biozym Diagnostik, Olendorf, Germany 
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SafeSeal tips 100 µl Biozym Diagnostik, Olendorf, Germany 
Syringe driven filter units 0.22 µm Millipore Corporation, Bedford, USA 
Syringes 10 ml Becton Dickinson S.A., Fraga, Spain 
Syringes 2 ml Becton Dickinson S.A., Fraga, Spain 
Tissue culture plates, 24 well BD Falcon, Heidelberg, Germany 
2.1.9 Appliances 
Biofuge pico Heraeus Instruments, Hanau, Germany 
BD FACSAria Cell Sorting System BD Biosciences, Heidelberg, Germany 
Casy 1 Cell Counter Schärfe System, Reutlingen, Germany 
Cell Culture Incubator CO2-Auto-Zero Heraeus, Hanau, Germany 
Centrifuge J6M-E Beckmann, München, Germany 
Confocal Microscope LSM 510 META Carl Zeiss AG, Hallbergmoos, Germany 
E max Precision Microplate Reader Molecular Devices Co.,Sunnyvale, USA 
Eppendorf pipettes Eppendorf, Hamburg, Germany 
FACS-Calibur Flow Cytometer BD Biosciences, Heidelberg, Germany 
Gradient Cycler PTC 200, MJ Research BioRad Laboratories, München, Germany 
Invert Fluorescence Microscope Axiovert 200M Carl Zeiss AG, Hallbergmoos, Germany 
Invert Fluorescence Microscope  
Axiovert S100 
Carl Zeiss AG, Hallbergmoos, Germany 
LaminAir HLB 2448 GS Heraeus, Hanau, Germany 
Light Cycler ROCHE Roche Diagnostics, Manheim, Germany 
Megafuge 1.0 Heraeus Sepatech, Osterode, Germany 
Milli Q Water System Millipore S.A., Molsheim, France 
Eppendorf Multipipette Eppendorf, Hamburg, Germany 
Multipipette Finn Labsystems GmbH, Quickborn, Germany 
NanoDrop Spectrophotometer ND-1000 Peqlab Biotechnologie GmbH, Erlangen, 
Germany 
Rotations Microtome HM350 Microm, Heidelberg, Germany 
Scale Sartorius R160P Sartorius, Göttingen, Germany 
Shandon Hypercenter XP GMI, Ismaning, Germany 
Varifuge 3.2 RS Heraeus Sepatech, Osterode, Germany 
Ventana NexES-System Ventana Medical Systems, Frankfurt, Germany 
Vortex REAX 2000 Heidolph Instruments, Schwabach, Germany 
Waterbath GFL 1083 GFL mbH, Burgwedel, Germany 
2.1.10  
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2.1.11 Software 
Adobe Photoshop 6.0 Adobe Systems GmbH, München, Germany 
AxioVision v.4.6 Carl Zeiss AG, Hallbergmoos, Germany 
AxioVision Release v.4.5 Carl Zeiss AG, Heilbergmoos, Germany 
BD Cell Quest Pro v.4.0.2  BD Bioscience, Heidelberg, Germany 
GeneSpring GX 7.5.1 Agilent Technologies Inc., CA, USA 
Light Cycler Software ROCHE v.3.5 Roche Diagnostics, Manheim, Germany 
LSM Image Browser Carl Zeiss AG, Hallbergmoos, Germany 
LSM Release v.4.2 Carl Zeiss AG, Hallbergmoos, Germany 
Microsoft Office 2003 Microsoft Deutschland GmbH, 
Unterschleißheim, Germany 
Origin 5.0 OriginLab Corp., Northampton, MA., USA 
Reference Manager 11 The Thomson Co., Carlsbad C.A., USA 
SoftMax Pro v.5 Molecular Devices Co.,Sunnyvale CA., USA 
SPSS 15.0 SPSS GmbH Software, München, Germany 
Win MDI 2.9 TSRI, Scripps, Fl., USA 
 
2.2 Methods 
2.2.1 Cell preparation and culturing 
2.2.1.1 Primary fibroblasts culturing 
Primary fibroblasts from invasive ductal breast carcinomas (PF27T, PF53T, PF37T) were 
derived from fresh resected tumor surgery specimen, kindly provided by the department  
of Pathology, University of Regensburg. Normal skin fibroblasts VF1 were resected from 
healthy tissue, kindly provided by department of Hematology, University of Regensburg. All 
types of tissue were cultured as described earlier (Kunz-Schughart et al., 2001b). Briefly, 
biopsy material was incubated with penicillin (5000 U/ml) and streptomycin (5 ng/ml) after 
removal of adipose tissue for 30-60 min, then sliced into 1-4 mm3 fragments and transferred 
into culture flasks that were kept in an incubator at 37°C for about 1-2 h in upright position. 
After attachment, tissue fragments were covered with special enriched growing medium 
(DMEM with 20% FCS and high glucose – 25 mM) and cultured in a humidified atmosphere 
(5% CO2 in air, 37°C), see chapter 2.2.1.3. When sufficien t outgrowth of cells was 
achieved, cells were enzymatically harvested (see chapter 2.2.1.3), tissue leftovers were 
removed via filters (cell strainer), and the cell suspension was transferred into T75 tissue 
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culture flasks in standard medium (DMEM with 10% FCS and 5 mM glucose). After 
reaching subconfluence, cells were dissociated and frozen stocks were prepared from 
passage 1-2 cells using 90% FCS and 10% DMSO for storage in liquid N2 (see also chapter 
2.2.1.4). Cultures of primary fibroblasts were morphologically and immunohistochemically 
characterized with: anti-CD90 (AS02) antibody - THYmocyte differentiation antigen 1 
(directed against fibroblasts) – positive; anti-Cytokeratin 18 antibody (epithelial cell marker)  
– negative; anti-CD31 antibody called PECAM-1 – platelet endothelial cell adhesion 
molecule-1 (specific for endothelial cells) – negative, and α-SMA (α-Smooth Muscle Actin), 
which determines specificity for a donor myofibroblast fraction. For immunohistochemical 
staining, cells were cultured as monolayer on sterile microscope slides, and stained 
according to an established protocol (see chapter 2.2.1.8). 
For experiments, fibroblasts were subsequently recultured from the frozen stocks  
in complete DMEM with 10% FCS plus ingredients (see chapter 2.2.1.3) as routine 
monolayer and passaged twice before spheroid initiation (see chapter 2.2.1.4). 
2.2.1.2 Monocyte isolation, freezing and reculturing 
Leukocyte enriched blood concentrates were obtained from healthy donors using 
leukapheresis. Peripheral blood mononuclear cells (MNC) were isolated from the 
concentrate by density gradient centrifugation over Ficol/Hypaque and next washed with 
PBS (Spottl et al., 2001). Subsequently, monocytes were isolated from MNC by counter 
current centrifugal elutriation in a J6M-E centrifuge using a large-volume chamber (50 ml),  
a JE-5 rotor at 2500 rpm, and a flow rate of 111 ml/min in Hanks’ balanced salt solution 
supplemented with 8% autologous human serum (Sanderson et al., 1977). Through 
adjustment of pump pressure against centrifugal force of cells, the cells were sorted 
according to their size and weight (the larger and heavier cells the more pressure power 
must be employed). Purity of elutriated MO taken for spheroid experiments was >90% as 
determined by morphological criteria and routine immunophenotyping (Krause et al., 1998). 
In most experimental series, freshly isolated MO were applied for co-culturing. However, for 
some settings, freshly isolated MO were centrifuged and resuspended at a concentration  
of 1x107 per 1 ml of medium to prepare frozen stocks. 60% RPMI-1640 medium, 30% FCS 
and 10% DMSO on ice was used as freezing medium and monocytes were rapidly 
transferred into cooled CRYO.S tubes. Cells were freezed gradually at -20°C, -80°C and 
finally stored in liquid N2 (-196°C). 
For recultivation, MO stocks were taken from the liquid N2, thawed in a water bath (37ºC) 
and rapidly transferred into PP test tube previously filled with 30 ml of standard medium. 
The MO suspension was then centrifuged at 1500 rpm for 10 min, medium was removed 
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and 1 ml of fresh standard medium was added to the cell pellet for resuspension. The 
number of viable cells was determined using the CASY-1 cell analyzer system and MO 
were immediately used for experiments following preparation of appropriate cell 
concentration. 
2.2.1.3 Routine monolayer cultures 
All breast tumor cell lines and fibroblasts were routinely cultured as adherent monolayers  
in tissue culture flasks (75 cm3 or 175 cm3). Standard conditions for incubation were 37ºC, 
5% CO2 in a humidified incubator. Cells were kept in Dulbecco’s Modified Eagle Medium 
(DMEM) containing 0.2% phenol red with 5% fetal calf serum (FCS) and 100 U/ml penicillin 
plus 100 µg/ml streptomycin (standard medium). The cell number was chosen according  
to doubling time (see Tab. 2.5); so that the cultured cells can be transferred one time per 
week in a subconfluent state (fibroblasts) or in exponential growth state (breast tumor cell 
lines). Medium was renewed every second day. 
Tab. 2.5 Number of cells routine seeded for monolayer culturing and the corresponding 
culture doubling times of the different cell  
Cells Surface of tissue culture flask Mean 
doubling 
time (h) 
75 cm3 175 cm3 
Fibroblasts 0.5 x 106 1.0 x 106 35 – 120* 
BT474 0.5 x 106 1.0 x 106 68 
T47D 0.3 x106 0.6 x106 48 
MCF-7 0.2 x 106 0.4 x 106 29 
BT549 0.2 x 106 0.4 x 106 35 
Hs578 0.2 x 106 0.4 x 106 52 
* VF1 - 35 h; PF27T - 75 h; PF37T, PF53T - 120 h. Doubling times for fibroblasts may increase 
with number of passages. 
Exponentially growing breast tumor cell lines or subconfluent fibroblast were washed with 
phosphate buffered saline (PBS), and dissociated by enzymatic and mechanic means using 
a 0.05% trypsin-0.02% EDTA solution in PBS. The incubation time was 0.5 – 2.5 min, 
dependent on cell line, at 37ºC. Detachment of the cells was microscopically monitored and 
cell suspension was transferred into 50 ml tubes containing sufficient amounts of standard 
medium, to stop enzyme activity. The cell suspension was centrifuged (450 g, 5 min), 
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supernatant was removed and pelleted cells were resuspended in 10 ml or 20 ml  
of standard medium (depending on estimating cell concentration). 100 µl of the cell 
suspension was used for estimating cell numbers and concentrations, respectively. This 
aliquot of cells was added to 9.9 ml of CASYton (dilution liquid for cell cultures) and cell 
number was counted using the CASY1 cell analyzer. The rest of the cell suspension was 
centrifuged again and pelleted cells were resuspended to a concentration of 1x106 cells/ml. 
2.2.1.4 Freezing and recultivation of adherent cells 
Frozen stocks were prepared following dissociation, counting and centrifugation of early 
passage cells. Pelleted cells were resuspended in cold freezing medium cells with  
a concentration of 1x106 cells/ml (90% FCS + 10% dimethyl sulfoxide, DMSO) and rapidly 
transferred into cooled CRYO.S tubes on ice. Cells were freezed gradually at -20 ºC, -80 ºC 
and finely stored in liquid N2 (-196ºC). For subsequent recultivation, cell stocks were taken 
from the liquid N2, rapidly thawn in a waterbath (37ºC), immediately transferred into a cell 
culture flask filled with double volume of growing medium (20 ml in T75 culture flask) and 
placed in 37ºC. After minimal time of 30 min and monitoring of cell attachment, medium 
was renewed, cells were passaged at least twice before usage. Breast tumor cells entering 
experiments were transferred for a maximum of 20 passages (100-120 cumulative 
population doublings) starting with the passage purchased. Fibroblasts were used only up 
to passage 7 (≤ 40 cumulative population doublings) to avoid effects due to cell 
senescence. 
2.2.1.5 3-D mono- and co-cultures 
Multicellular spheroids (MCS) were generated according to the liquid overlay technique 
(Konur et al., 1996; Kunz-Schughart et al., 2001a, Friedrich et al., 2009). using agarose-
coated 96 well plates. To coat plates, 1.5% agarose was dissolved in DMEM, autoclaved 
for at least 20 min and transferred into the wells of a 96-well plate at a temperature of 
approximately 60ºC (50 µl/well). The coated plates were left for 10-20 min uncovered to 
cool down agarose and evaporate moisture. Agarose-coated plates were hermetically 
sealed and used up to one week. Storage of plates was at room temperature in the dark. 
To initiate spheroid cultures, defined concentrations of single cell suspensions were 
prepared from exponentially growing tumor cells or subconfluent fibroblast monolayers 
(Tab. 2.6 and Tab. 2.7). 200 µl of the cell suspension was seeded per well with a 
multipipette. After four days of standard culturing (see chapter 2.2.1.5) cells created round-
shaped aggregates (without central necrosis). The number of cells was optimized to obtain 
a desired spheroid diameter at day 4 in culture (>300 µm, <400 µm). In order to determine 
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the appropriate seeding density, experiments with different cell numbers used for their 
inoculation into agarose-coated wells were performed. 
To determine the number of viable cells, spheroids were transferred with a Pasteur pipette 
into a 15 ml tube and washed with cold PBS. After removing the PBS, washed spheroids 
were dissociated by incubation with a 500 ml of 0.17% trypsin/0.07% EDTA in PBS, at 37ºC 
for 5 min (500 µl) and mechanic means (gentle pipetting). Enzyme activity was stopped by 
addition of 500 µl of supplemented DMEM. The whole volume of cell suspension (1 ml) was 
added to 9 ml of CASYton and cell number was counted using the CASY1 cell analyzer. 
Subsequently, the number of cells per spheroid was calculated. 
Tab. 2.6 Cell numbers inoculated to initiate 3-D cultures from breast carcinoma cell lines. 
Cell line Cell number per well (200 ml) 
BT474 2000 
BT549 4500 
Hs578T 7000 
MCF-7 750 
T47D 3000 
Tab. 2.7 Cell numbers inoculated to initiate 3-D cultures from tumor-associated fibroblasts. 
Cells Cell number per well (200 ml) 
PF27T 4000 
PF37T 4000 
PF53T 4000 
VF1 4000 
In order to co-culture spheroids with monocytes (MO), 3-D aggregates were generated as 
described for spheroid mono-culturing. At day 4 in culture, 100 µl of the supernatant was 
replaced with 100 µl of a freshly prepared monocytes suspension (1x104 MO per spheroid) 
in supplemented standard medium. Monocyte migration was monitored as a function  
of time in co-culture or after defined time intervals. e.g. 4 h, 20 h and/or 40 h following 
monocyte addition. In most experimental series, spheroid co-culture were dissociated and 
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flow cytometric analyses of single cell suspensions were performed to quantify the 
proportion of migrated monocytes. 
2.2.2 Experimental designs to affect cells in co-culture 
2.2.2.1 Manipulation of the fibroblast milieu 
2.2.2.1.1 Wash-out experiments 
To reduce the level of paracrine factors such as CCL2 in the milieu of fibroblast spheroids, 
100 µl of conditioned medium (1/2 of total volume) was replaced with fresh medium. This 
process was repeated 6 times to obtain a 1:64 dilution of conditioned medium. In step 6, 
100 µl supernatant was replaced by 100 µl the MO suspension (1x104 MO per spheroid).  
In parallel, supernatants were collected, frozen (-80°C) and used for CCL2 level 
determination by ELISA (see chapter 2.2.6). An aliquot of the spheroids (≥48) was collected 
and dissociated (see chapter 2.2.1.4) to estimate cell number per spheroid and calculate 
cellular CCL2 release rates. Flow cytometric analysis of cell distribution in spheroid  
co-cultures was performed after 2 h, 4 h, 6 h, 8 h and 20 h of incubation. Experiment were 
performed in triplicate. 
2.2.2.1.2 Addition of rhCCL2 to fibroblasts 3-D co-cultures 
Two hours before the addition of MO, rhCCL2 was added to fibroblast spheroids by 
replacing 100 µl of the supernatant by 100 µl of fresh medium supplemented with rhCCL2 
in the following concentrations: 0.04 µg/ml and 0.4 µg/ml for TAF, 0.004 µg/ml and  
0.04 µg/ml for VF1 spheroids. The final concentrations of rhCCL after the addition of  
1x104 MO/spheroid (suspended in 100 µl of medium) were: 0.02 µg/ml and 0.2 µg/ml (TAF) 
or 0.002 µg/ml and 0.02 µg/ml (VF1). After 4 h of incubation in a humidified atmosphere 
(37°C), spheroids ( ≥48) were collected and dissociated (see chapter 2.2.1.5). Finally, flow 
cytometrical analysis of MO migration, as described in chapter 2.2.4.3 was carried out. 
Experiment were performed in triplicate. 
2.2.2.2 Modulation of the MO suspension 
2.2.2.2.1 Application of blocking toxins 
To block the signaling pathways of various chemokines, MO were pretreated with two 
different toxins before co-culturing with fibroblast or tumor cell spheroids. Pertussis toxin 
(PTX) holoenzyme and PTX B-oligomer were applied at concentrations of 1 ng/ml, 10 ng/ml 
and 50 ng/ml. Cholera toxin (ChTX) holoenzyme or ChTX B-subunit were used  
at concentrations from 0.1 ng/ml up to 50 ng/ml. PTX B-oligomer and ChTX B-subunit were 
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used as negative controls. These subunits bind to the cell surface but they do not have the 
enzymatic activity of the toxin. MO (0.2x106/ml) were incubated for 30 min in 15 ml tubes,  
at room temperature with the toxins diluted in supplemented DMEM. The MO number and 
its viability were then estimated using the CASY-1 cell analyzer system and 1x104 cells  
in 100 µl were added to each well containing fibroblast spheroids. After 4 h of incubation  
in a humidified atmosphere (37°C), the effect of to xins on MO migration into spheroids was 
recorded via flow cytometry following co-culture and dissociation (see chapters 2.2.1.5, 
2.2.4.3). Experiment were performed in triplicate. 
2.2.2.2.2 Application of blocking antibodies 
To exclusively block receptor CCR2A/B, the specific monoclonal antibody DOC-3 (kindly 
provided by Prof. Matthias Mack; University of Regensburg, Germany) was used and tested 
for TAF-MO and Hs578T-MO co-cultures. Control experiments were performed with 
blocking antibody CD11b (MAC-1) which should be irrelevant for MO migration.  
MO (0.2x106/ml) were incubated in 15 ml tubes for 30 min at room temperature with DOC-3 
or CD11b or with corresponding isotype controls (IgG1 and IgG2a, respectively) and then 
added to spheroids. DOC-3 antibody was applied in concentration of 1 and 10 µg/ml. After 
incubation, the MO number and viability were estimated using the CASY-1 cell analyzer 
system. 1x104 MO incubated with DOC-3 or CD11b in 100 µl were added per well each 
containing TAF or Hs578T (only MO incubated with DOC-3) spheroids. Spheroid  
co-culturing was carried out in presence of antibodies. After 20 h (fibroblasts spheroid  
+ MO) or 40 h (Hs578T spheroid + MO) of incubation in a humidified atmosphere at 37°C, 
the effect of substance on MO migration was monitored via flow cytometry following 
spheroid dissociation according to chapters 2.2.1.5 and 2.2.4.3. Incubation was performed 
in the presence of antibodies. Cell viability was established with CASY-1 cell analyzer. 
Experiment were performed in triplicate. 
2.2.3 Immunohistochemistry 
2.2.3.1 Immunohistochemical characterization of fibroblasts 
For immunohistochemical staining, freshly isolated fibroblasts (see chapter 2.2.1.1) were 
seeded on sterile microscope slides (2.5 x 104 per slide) and cultured in standard medium 
(see chapter 2.1.2.3). After 2-3 days of culturing, slides were fixed in cold acetone (10 min), 
air-dried and stained applying the ABC-method (or stored in -20°C). Primary and secondary 
antibodies used for staining and their working concentrations are listed in Tab. 2.8. 
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Biotinylated goat-anti-mouse antibody (1:100) was used as secondary antibody. Staining 
was performed according to the protocol given in Tab. 2.9. 
Tab. 2.8 Concentrations of antibodies used for immunohistochemical characterization of 
fibroblasts. 
Antibody Stock 
Concentration 
Working 
Concentration 
Dilution 
AS02 0.2 mg/ml 4 µg/ml 1:50 
CK18 2 mg/ml 200 µg/ml 1:100 
CD31 345 mg/L 4.3 µg/ml 1:80 
α-SMA 0.1 mg/ml 1 µg/ml 1:100 
2.2.3.2 Immunohistochemistry on paraffin section 
Paraffin sections of spheroids were first rehydrated (2x 5 min Xylene; 2x propanol 100%;  
2x ethanol 96%; 2x ethanol 70%; each time 5 min) and then stained via the ABC-method 
(described in chapter 2.2.3.1). A monoclonal mouse-anti-human CD45 antibody, 1:600 
(stock concentration 450 mg/L) was used. The staining was performed automatically using 
the Ventana NexES System. After the staining procedure, microscope slides with spheroids 
sections were washed (10 min) in tap water with additive of rinsing agent and finally 
dehydrated according to the protocol given in Tab. 2.9 steps 14-17 before coverage with 
entellan. 
Tab. 2.9 Staining protocol for immunohistochemical antigen detection in cuvette system 
Nr. Substance Conditions Step 
1. 2% H2O2 in methanol (fresh) 15 min blockade of tissue 
peroxides  
2. PBS 5 min washing 
3. 2.5% BSA in PBS 90 min, 4ºC blockade of unspecific 
protein bindings 
4. Primary antibody in 1% BSA/PBS 16 h, 4ºC binding of specific 
antibody  
5. PBS 3 x 5 min washing 
Materials and Methods  34 
 
6. Biotinylated goat-anti-mouse 
secondary antibody (1:100) 
45 min, 20ºC binding of secondary 
antibody 
7. PBS 3 x 5 min washing 
8. Streptavidin-biotin-peroxidase 
(1:1:100) 
45 min, 20ºC strengthening  
9. PBS 3 x 5 min washing 
10. DAB Chromogen in Substrate Buffer 
(1:50) 
5 min, 20ºC color development 
11. distilled H2O 5 min washing 
12. Hematoxylin  1 min counter staining 
13. Running tap water 3 min washing 
14. Ethanol 70% 5 min (1x) dehydration  
15. Ethanol 96% 5 min (2x) dehydration 
16. Propanol 100% 5 min (2x) dehydration 
17. Xylene 5 min (2x) dehydration 
18. Entellan  covering 
2.2.4 Flow cytometric (FC) analysis 
2.2.4.1 Technology 
Flow cytometry is a method for analyzing particles and cells in suspension. Among others, 
expression of cell surface and intracellular molecules can be monitored in single  
or simultaneous multi-parameter analysis of single cells. 
In a flow cytometer, cells in suspension are hydrodynamically focused in a sheath of fluid 
and then presented to a laser (a source of light excitation). The cells/particles passing 
through the beam scatter the light, which is detected as forward scatter (FSC) and side 
scatter (SSC) and analyzed by a series of filters and photomultiplier tubes that convert the 
light signal into electrical impulses. In normal cells, FSC correlates with the cell size and 
SSC relates to the cell density. Fluorochromes used for staining emit light when excited by 
a laser with corresponding excitation wavelength. 
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2.2.4.2 Monocyte characterization 
Monocytes (5x106 per test) were stained with antibodies in established dilution to avoid 
non-specific binding. Depending on available reagents, one step direct staining or two step 
indirect staining was performed. Cells were incubated with antibody in each staining step 
for 30 min at 4°C. To wash out excessive, non-bound  antibody, PBS containing 1% FCS 
was added; the cells were spun down at 450 g and resuspended in PBS. If needed, 
secondary antibody was added and incubation and washing step was repeated. Stained 
cells were diluted in 100 µl of PBS and transferred into polypropylene tubes for flow 
cytometric measurement. The antibodies applied to characterize and also to sort MO are 
listed and detailed in Tab. 2.10. 
Tab. 2.10 Antibodies used for monocytes staining. 
 
Antigen Primary Ab Stock 
Concentration and 
Dilution of Ab 
Secondary Ab Volume and 
Dilution of Ab 
CC
R2
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CCR2 DOC-3 1.43 µg/µl; 3 µl, 
undiluted 
goat-anti-mouse-
FITC 
10 µl, 1:10 
Isotype 
Control 
IgG1 1 µg/µl; 4 µl 
undiluted 
goat-anti-mouse-
FITC 
10 µl, 1:10 
CD
14
/C
D
16
 
ex
pr
es
si
oCD14 anti-CD14-
PE/Cy5 
5 µl undiluted _ _ 
CD16 anti-CD16-
PE 
5 µl undiluted _ _ 
CD
14
/C
D4
9e
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D1
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CD11a anti-CD11a 1 µg/µl, 4 µl 
undiluted 
goat-anti-mouse-
PE 
10 µl, 1:100 
CD11b anti-CD11b 1 µg/µl, 4 µl 
undiluted 
goat-anti-mouse-
PE 
10 µl, 1:100 
CD49e anti-CD49e-
FITC 
5 µl undiluted _ _ 
CD14 anti-CD14-
PE/Cy5 
5 µl undiluted _ _ 
 
The samples were measured on a FACS-Calibur flow cytometer. Samples labeled with 
FITC, PE, PE/Cy5-conjugated antibodies were measured in channel FL1, FL2, FL3, 
respectively (for excitation and emission spectra see table 2.10, chapter 2.2.4.4). For each 
sample 2x104 events were collected and analyzed using the associated CellQuest Pro 
software. Data were visualized in dot plots or histogram plots. 
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2.2.4.3 Analysis of monocytes from co-cultures 
Prior to flow cytometric analysis, spheroid co-cultures were dissociated and single cell 
suspensions were prepared as described in chapter 2.2.1.5 To determine fibroblast  
or tumor cell to MO ratio, a minimal number of 48 co-cultures was collected per sample and 
transferred into 15 ml tubes. Spheroids were washed 3x in cold PBS to remove monocytes 
loosely attached to the spheroid surfaces and the rest of medium, and were then 
dissociated as described in chapter 2.2.1.5. Finally, cells were washed with PBS containing 
1% FCS. For fibroblast staining, cells were left 10 min in contact with 1% FCS in PBS  
in order to block unspecific binding. Cells (1x104 - 2x104 cells per sample, depending on cell 
type) were incubated with antibodies for 30 min at 4° C, then washed with PBS (1% FCS) 
and pelleted at 450 g for 5 min. Stained cells were diluted in 100 µl of PBS and transferred 
into polypropylene tubes for flow cytometric measurement. 
Tumor cell to MO ratio was estimated after staining with an APC-conjugated anti-CD45 
antibody which is specific for monocytes. FSC, SSC and FL4 fluorescence signals were 
recorded. Regions/gates were defined in the SSC vs. FL4 dot plot diagrams for MO and 
tumor cells discrimination (Fig. 2.1.a). To distinguish monocytes from fibroblasts, cells were 
stained with a FITC-conjugated fibroblasts specific antibody AS02 (stock concentration  
0.2 µg/µl; dilution 1:25). FSC, SSC and FL1 fluorescence signals were recorded. 
Regions/gates were defined in the SSC vs. FL1 dot plot diagrams for MO and fibroblasts 
discrimination (Fig. 2.1.b). All experiments were performed in triplicate. In Tab. 2.11 
excitation and emission spectra for fluorophores are listed. 
 
Fig. 2.1 Representative flow cytometric dot plot diagram of dissociated spheroids co-cultures. 
(a) R1 – region/gate 1 of fibroblasts (F) stained with FITC-conjugated AS02-antibody, R2 – 
region/gate 2 of unstained monocytes (MO). (b) R1 – region/gate 1 of unstained tumor cells 
(TC) with FITC-conjugated AS02-antibody, R2 – region/gate 2 of MO stained with APC-
conjugated CD45-antibody. 
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Tab.2.11 Excitation and emission spectra. 
Fluorophore Excitation (nm) Emission (nm) 
FITC 495 519 
PE 480;565 578 
PE/Cy5 480;565;650 670 
APC 650 660 
2.2.5 Fluorescence Activated Cell Sorting (FACS) 
2.2.5.1 Technology 
FACS allows the isolation of cells (not only analysis) from heterogenous populations based 
on their spectral characteristics. The FACS device used for the present study is a high-
speed sorter with a piezocristal vibration unit and a nozzle system leading to the formation 
of droplets from the stream as soon as the hydrodynamically focused cells have passed the 
laser beam. A positive or negative electrical charge is applied to the droplets containing 
cells of interest. The charged droplets then fall through an anode/cathode deflection system 
that diverts the droplets into containers as detailed in Fig. 2.2. 
2.2.5.2 Isolation of MO subpopulations for co-culturing 
To isolate monocyte subpopulations, freshly isolated MO were double stained with  
PE-conjugated anti-CD14 and PE/Cy5-conjugated anti-CD16 antibodies (see Tab. 2.10, 
chapter 2.2.4.2). About 4x107 MO were centrifuged and antibodies, each in volume of  
100 µl were added to cell pellet. The cells were left at 4°C for 30 min, followed by three 
washes with PBS. Next, 1 ml of PBS was added and cells were filtered and separated via 
Fluorescence-activated cell sorting. SSC, FSC, FL2 (for PE fluorescence), FL3 (for PE/Cy5 
fluorescence) signals were recorded. Regions/gates were defined in the FL2 vs. FL3 dot 
plot diagrams for discriminating MO subpopulations. Four regions/gates were defined:  
R1 - CD14++CD16-, R2 - CD14++CD16+, R3 – CD14++CD16++, R4 – CD14+CD16++. 
Sorted MO fractions were collected into PP tubes containing 1 ml of FCS. Cell 
concentration was measured using the CASY1 cell analyzer and adapted to obtain  
1x104 MO in 100 µl for addition to the prepared fibroblast spheroids (1x104/sphreoid, see 
chapter 2.2.1.5). The cells were co-cultured for 40 h to compare their migration capacity. 
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Fig. 2.2 FACS system. FACS uses the principle of hydrodynamic focusing for presenting cells 
to a laser. A suspension of cells is forced at high pressure through a vibrating nozzle to 
create tiny charged droplets, each containing a single cell. Particles/cells passing through the 
beam will scatter the light, which is detected as forward scatter and side scatter. The 
combination of scattered and fluorescent light is detected and analyzed. Droplets with 
different cell types are deflected by a static electrical field and directed into separate 
collection vials. 
Each MO fraction was added to 48 fibroblast spheroids. To exclude artifacts, which could 
result from staining and/or sorting procedures, the following controls with whole blood 
monocytes were prepared: unsorted/unstained, unsorted/stained and sorted/stained. 
Experiment was performed in triplicate. 
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2.2.5.3 Isolation of cells from co-cultures for further analysis 
Sorting of cells (with FACSAria Cell Sorting System) was also used to separate co-cultured 
TAF and MO. Spheroids were trypsinized (chapter 2.2.1.5) and stained with fibroblasts 
specific antibody (AS02-FITC, see chapter 2.2.4.3). FSC, SSC and FL1 fluorescence 
signals were recorded. Regions/gates were defined in the SSC vs. FL1 dot plot diagrams 
for MO-fibroblast discrimination and cell population were sorted. Purity of population was 
96-98% for MO and 98-99% for fibroblasts. To achieve cell numbers sufficient for 
microarrays experiments, 24 plates each with 96 spheroids were required. Experiment was 
performed in triplicate. 
2.2.6 ELISA assay – determination of CCL2 concentration 
Supernatants of fibroblasts and tumor cell lines were collected 4 days after initiation  
of spheroids or 24 h after last change of medium for monolayer cultures, aliquoted and 
stored at -80°C. Under these conditions of storage no loss of the cytokine immunoreactivity 
is described. However, levels of CCL2 were always determined after a maximum of  
6 weeks of storage. CCL2 levels in the supernatants of various mono- and co-cultures were 
measured with a commercial ELISA kit (Human CCL2/MCP-1 Quantikine, R&D Systems) 
after subsequently thawing the samples. CCL2 concentration was determined in cell culture 
supernatant according to the manufacturer’s manual. In brief, samples, standards and 
controls were pipetted into microplates pre-coated with monoclonal antibody specific for 
CCL2 and incubated 2 h at room temperature. After washing away unbound substances, 
HRP-labeled antibody (detection antibody) was added and incubated for 1 h. Unbound 
detection antibody was washed away. Then, a detection reagent (e.g. streptavidin/HRP) 
was added to the wells. The plate was washed again and substrate solution (TMB/hydrogen 
peroxide) was added. Color developed relative to the amount of CCL2 bound in the initial 
step. The color development was stopped after 20 min by the addition of sulphuric acid and 
the signal intensity was measured with an E max Precision Microplate Reader. The 
cytokine content was measured in pg/ml and referred to cell number per spheroid. 
2.2.7 RNA expression analysis 
2.2.7.1 Total RNA isolation 
Total RNA for real-time PCR was isolated by TRIzol Reagent following the manufacturer’s 
instructions. After adding the proper volume of TRIzol Reagent and homogenization, 
samples were incubated for 5 min at room temperature. 0.2 ml of chloroform were added 
per 1 ml of TRIzol. Tubes were shaken vigorously by hand for 15 sec and incubated 3 min 
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at room temperature. Samples were then centrifuged at 12,000 x g for 15 min at 4º C. The 
upper colorless aqueous phase containing RNA was transferred to a fresh tube. 
Subsequently, 0.5 ml of isopropyl alcohol per 1 ml of TRIzol were added, samples were 
incubated at room temperature for 10 min and centrifuged at 12,000 g for 10 min at 4º C. 
After centrifugation, supernatant was removed and the RNA pellet was washed with 75% 
ethanol. The samples were mixed by vortexing and centrifuged at 7,500 x g for 5 min  
at 4º C. At the end of the procedure, the RNA pellet was briefly dried and dissolved  
in RNase free water. Concentration and purity of RNA was determined by 
spectrophotometry (NanoDrop) using 2 µl of undiluted RNA. Pure RNA has an A260nm/A280nm 
absorbance ratio of 2.0. 
2.2.7.2 Reverse transcription 
First-strand cDNA synthesis from RNA was performed using the reagents and reaction 
conditions specified in Tab. 2.12. Control samples to identify potential contamination  
(no reverse transcriptase control and no RNA control) were prepared. The final volume  
of the reaction was 20 µl. 
Tab. 2.12 Reagents and conditions for cDNA synthesis 
 total RNA 1 µg  
 random hexamers 0.2 µg  
 H2ODEPC to 11 µl of vol. 70ºC, 5 min; chill on ice 
RT-Mix: 5x M-MuLV RT buffer 4 µl  
 10x dNTPs Mix (10 mM) 2 µl  
 DTT (0.1 M) 2 µl 25ºC, 5 min 
 RevertAid M-MuLV RT 
(200 U/µl) 
1 µl 25ºC, 10 min 
37ºC, 60 min 
70ºC, 10 min 
4ºC 
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2.2.7.3 Real-Time PCR 
Real-Time PCR is a quantitive PCR method for the determination of copy number of PCR 
templates such as cDNA in a PCR reaction. In the present study an intercalator-based 
technology was applied, also known as SYBR Green method. This approach requires  
a double-stranded DNA dye in the PCR reaction which binds to newly synthesized double-
stranded DNA and gives fluorescence. The Real-Time PCR was performed using the 
QuantiTect SYBR Green PCR Kit (Qiagen) following the manufacturer’s instructions. The 
reaction condition and amount of reagents are given in Tables 2.13 and 2.14 The final 
volume of reaction was 20 µl. For amplification with CCL2 primers, 40 cycles were 
performed and for amplification with 18S primers (control, housekeeping gene) 35 cycles 
were performed. 
Tab. 2.13 Real-Time PCR: Reaction Mix 
2x QuantiTect SYBR Green PCR 10 µl 
Primer Mix (20 µM) 1 µl 
cDNA template 2 µl 
H2ODEPC 7 µl 
Tab. 2.14 Real-Time PCR: Real-Time Cycler Conditions 
Step Time Temperature 
PCR initial activation 15 min 95ºC 
3-step cycling    
 Denaturation 15 sec 95ºC 
 Annealing 20 sec 58ºC 
 Extension 25 sec 72ºC 
Cycle nr. 35 (18S) or 
40 (CCL2) 
  
 
Materials and Methods  42 
 
2.2.7.4 cDNA microarrays 
2.2.7.4.1 Technological basics 
A microarray is defined as a collection of microscopic spots arranged in an array and 
attached to a solid surface. These spots, referred to as probes, are designed such that 
each probe binds a specific nucleic acid sequence corresponding to a particular gene 
through a process termed hybridization. The sequence bound to a probe, referred to as the 
target, is labeled with some kind of dye such as a fluorophore. The level of binding between 
a probe and its target is quantified by measuring the fluorescence emitted by the labeling 
dye when scanned. This signal provides a measure for the expression of a specific gene 
containing the target sequence. 
2.2.7.4.2 Analysis of migrated MO versus non-migrated 
The experiment was designed to analyze the gene expression profile of migrated versus 
non-migrated MO and included: 1) co-culturing of MO with fibroblast spheroids and 
subsequent sorting of co-cultured cells; 2) gene expression analysis. 
1) Co-culturing and separation of MO and fibroblast spheroids for cDNA microarrays 
To compare migrating and non-migrating monocytes, 24 plates, each with 96 spheroids 
were prepared according to the protocol described in chapter 2.2.1.5. MO were co-cultured 
with fibroblasts spheroids for 4 h, to allow complete MO migration. To collect migrating 
monocytes, spheroids were placed in 15 ml tubes and washed 3 times with 10 ml of PBS 
and then dissociated by enzymatic means (see chapter 2.2.1.6). Non-migrated MO 
remaining in culture dishes were collected together with medium, centrifuged (450 g,  
10 min) and washed with PBS. Both MO populations were stained with FITC conjugated 
AS02 antibody (1:25) and sorted as described in chapter 2.2.5.3. A set of controls was 
prepared to exclude artifacts which could occur as a result of incubation, staining or sorting 
(Tab. 2.15). Samples and controls were then lyzed and RNA was subsequently isolated 
(see 2.2.7.1). 
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Tab. 2.15 Samples and controls for cDNA microarrays 
 Incubation time/ 
environment 
Stained Run through 
sorter 
Control 0 
untreated MO 
- no no 
Control 1 
MO kept on ice 
4 h, 4°C yes yes 
Control 2 
MO kept in Teflon bag* 
4 h, 37°C, 
Teflon bag 
yes yes 
MO outside 
non-migrating MO** 
4 h, 37°C, 
culture dish 
yes yes 
MO inside 
MO migrated into fibroblast 
spheroids 
4 h, 37°C, 
spheroids inside 
yes yes 
*  Teflon bag provide optimal culturing conditions 
** Non-migrating MO during incubation time stayed in contact with agar-coated 96 well plate 
(culture dish) 
 
2) Gene expression analysis 
Total RNA for cDNA microarrays was prepared from cell pellets using the “RNeasy Mini Kit” 
according to the manufacturer’s instructions. RNA concentration and purity was determined 
by spectrophotometry using a 1:30 diluted RNA sample. Pure RNA has an A260nm/A280nm 
absorbance ratio of 2.0. 
Preparing and labeling of cDNA hybridization, washing and scanning were performed 
according to the One-Color Microarray-Based Gene Expression Analysis Protocol (Agilent 
Technologies). Fig. 2.3 is a standard workflow for sample preparation and array 
hybridization design. Microarrays data clustering and comparative analysis was done with 
the GeneSpring GX 7.5.1 software. 
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Fig. 2.3 The major steps in a cDNA microarray experiment. Isolated RNAs from both control 
and test samples are converted into cDNAs (reverse transcription). cDNAs are labeled with 
fluorescent probes (Cy3 - green and Cy5 - red). After hybridization and washing procedures, 
cDNA microarrays are scanned at 540 nm (green) and 630 nm (red), respectively, for the 
experimental channel. Finally, a two-channel Red-Green image is obtained. 
Black-colored spots signalize no hybridization; no detectable signal. Green-colored spots 
indicated less binding of the test samples than the control sample; down regulation. Yellow-
colored spots indicate equal binding between samples; constant regulation. Red-colored 
spots indicate greater binding of the test sample than the control sample; up–regulation.  
2.2.7.5 RNAi approaches 
2.2.7.5.1 Technological basics 
RNA interference (RNAi) is a phenomenon of post-transcriptional gene silencing (Fig.2.4) 
Introduction of double stranded RNAs (dsRNAs; typically >200 nt) into certain organisms 
and cell types causes degradation of the homologous mRNA. Because of potential antiviral 
response of mammalian cells, the dsRNA cannot be used for inhibiting gene expression. 
This response dsRNA degradation can be bypassed, however, by the introduction of short 
interfering RNAs (siRNAs; 20-25 nt) (Elbashir et al., 2001). 
In order to down regulate CCL2 expression in fibroblasts, different RNAi approaches were 
tested. 
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Fig. 2.4 RNAi – mechanism. Double stranded RNA is introduced into a cell and gets chopped 
up by the enzyme dicer to form siRNA. siRNA then binds to the RISC complex and is 
unwound. The antisense RNA complexed with RISC binds to its corresponding mRNA which 
is then cleaved by the enzyme and degraded, so that protein expression is abrogated. 
2.2.7.5.2 Experimental set-up to down-regulate CCL2 in fibroblasts 
Fibroblasts were seeded as monolayers in 24 well plate ((3-3.5)x104 cell/well) and 
incubated 24 h under standard culture conditions to reach a confluence level of about 50% 
at the time of transfection. The transfection mix using serum-free medium Opti-MEM I, the 
transfection reagent Oligofectamine and the siRNAs were prepared according to the 
protocol given in Tab 2.16. 
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Tab. 2.16 Transfection mix for siRNA transfection (amounts per well are given) 
Tube 1 Opti-MEM I 5.5 µl  
 Oligofectamine 2 µl mix; 10 min, 
room temperature 
Tube 2 Opti-MEM I 40 or 41.25 µl  
 siRNAs 1.25 or 2.5 µl 
(end concentration 200 nM) 
mix 
Tube 1 + Tube 2 mix; 15-20 min, 
room temperature 
The medium was changed one day and three days after transfection. At day four after 
transfection cells were dissociated according to a standard procedure (see 2.2.1.3) and 
seeded again as monolayers and as spheroid mono-cultures (see 2.2.1.3 and 2.2.1.5). 
Previous to the dissociation, supernatants were collected and frozen at (-80º) C to check 
CCL2 protein release from day 3 to 4 (24 h release rates) after transfection as described  
in chapter 2.2.6. The cells were cultured until day 7 after transfection. At day 7 supernatants 
were again collected and frozen both from monolayer and spheroid cultures for subsequent 
CCL2 protein analysis. Monolayer and spheroid cultures were then dissociated according  
to the routine procedures described in chapters 2.2.1.3 and 2.2.1.5, and the number  
of viable cells per well and per spheroid, respectively, was determined via the CASY1 cell 
analyzer system. Cell count analysis was performed at days 4 and 7 in culture to allow 
calculation of CCL2 protein release rates per cell. Parallel to samples transfected with 
siRNA potentially reducing target protein, control samples were run to identify artifacts due 
to down-regulation of gene expression through siRNA per se. As negative controls, short 
sense sequences of RNA corresponding to working dsRNAs were used. 
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The experiments performed in the present work to modulate CCL2 release from fibroblast 
monolayer and spheroid cultures included the following applications and modifications  
of the RNAi approach: 
 Different fibroblast cultures were tested: PF27T, PF53T, PF37T 
 Commercially available siRNA (siRNA Silencer from Ambion) were compared with self-
designed siRNAs (1 ds siRNA, 2 ds siRNA) 
 Different dissociations means (trypsin/EDTA, accutase, collagenase III) were applied 
 Additional fluorescence siRNA control - Alexa Fluor488 was included 
 CCL2 reduction on RNA level was verified by isolating and analyzing total RNA at day 4 
and day 7. The RNA was isolated via TRIzol, transcribed into cDNA and amplified with 
the Real-Time PCR technique as detailed in chapters 2.2.7.1-3. 
2.2.8 Statistical analyses 
Statistical significance, e.g. to verify differences between data sets of control and treated 
groups, was routinely evaluated using the nonparametric Mann-Whitney U test in the SPSS 
15.0 software. The relationship between CCL2 release and MO infiltration was assessed  
by linear regression analysis in the Origin 5.0 software program. Values of p<0.05 were 
considered to be statistically significant. 
 
Results  48 
 
3. Results 
The results chapter is divided into the three following sectors: 1) monitoring of MO migration 
into spheroids of breast tumor origin, 2) verifying influence of chemokines and specifically 
CCL2 on spheroidal MO migration and 3) trials of identifying migrated MO subpopulation.  
3.1 Migration of monocytes into spheroids of breast tumor origin 
3.1.1 Migration of monocytes into fibroblast spheroids 
Studies performed by Silzle et al. (Silzle et al., 2003), have shown that the proportion of MO 
migrating into spheroids of breast tumor-derived fibroblasts is significantly higher than  
in spheroids from normal skin and breast fibroblasts. To better understand this process, the 
migration kinetics of MO into spheroids of breast tumor-derived fibroblasts was monitored. 
At the time of MO addition spheroids were about 300-330 µm in diameter, consisted  
of (1.5-2)x103 cells and showed no central necroses. MO to fibroblasts ratios were 
estimated after 10, 20 and 40 h using flow cytometry (Fig. 3.1a). No significant difference  
in MO to fibroblast ratio was observed after 10, 20 and 40 h in three independent 
experiments indicating that MO migration is completed within 10 h. To determine the exact 
time required to complete MO migration, the MO to F ratio after 2, 4, 6, 8 and 20 h of  
co-culturing was determined. This experiment shows that MO migration is completed within 
only 4 h (Fig. 3.1b). Mean proportion of MO and fibroblasts in spheroid co-cultures after 
completing of MO migration is shown in Tab. 3.1. 
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Fig. 3.1 Monocyte migration into tumor-derived fibroblast spheroids. MO to fibroblasts 
proportion in PF27T spheroid co-culture was checked (a) 10, 20 and 40 h and (b) 2, 4, 6, 8 and 
20 h after addition of 1x104 MO per spheroid. The cell ratio (± SD) was determined using flow 
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cytometric analysis following spheroid dissociation. Columns in graphs show mean values 
and SD of three independent experiments with MO from 3 different healthy donors. 
Tab. 3.1 Mean proportion of cells (MO and fibroblasts) in spheroid co-cultures 4 h after 
addition of MO. 
 Percentage of monocytes 
in co-culture (%) 
TAF MO (%) F (%) SD 
PF27T 54.5 45.5 4.7 
PF37T 44.7 55.3 2.7 
PF53T 60.6 39.4 2.6 
3.1.2 Migration of monocytes into different breast tumor cell line spheroids 
Five breast tumor cell lines of different invasiveness were chosen and MO migration was 
proved. The aim of this experiment was to find out if/how MO invade breast tumor cells 
spheroids and compare outcomes with MO migration into fibroblast 3-D cultures. 
The chosen breast tumor cell lines were tested and adopted to produce spheroids with  
a mean diameter of about 350 µm and without central secondary necrosis at the day of MO 
addition. Depending on cell line, spheroids showed different packaging, from most round 
and compact BT474 spheroids to least compact spheroids created by MCF-7 cell line  
(see Fig. 3.2). In contrast to the tumor-derived fibroblast 3-D cultures, which are growth 
arrested, some of the tumor cell lines (BT474, MCF-7, T47D) still proliferate in spheroid 
culture and spheroid volume increases throughout culturing. Tab. 3.2 shows the average 
spheroid diameter for different cell lines at day 4 and day 6 after inoculation. Number  
of cells used for spheroid inoculation is given in Tab. 2.5, chapter 2.2.1.4. Mean proportion 
of MO and tumor cells in spheroid co-cultures after completing of MO migration is shown  
in Tab. 3.3. 
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Fig. 3.2 Representative spheroids derived from breast tumor cell lines. Phase contrast images 
were made 4 days after inoculation. Magnification of 10 x objective was used. (a) BT474; (b) 
BT549; (c) Hs578T; (d) MCF-7; (e) T47D. Bar = 100 µm applies to all images. 
Tab. 3.2 Diameter of spheroids originated from breast tumor cell lines at day 4 and day 6 after 
inoculation. 
Cell 
line 
Diameter of spheroids and SD (µm) 
day 4 day 6 
 average  SD average SD 
Hs578T 373 15 369 14 
T47D 371 6 402 3 
BT549 352 3 347 8 
MCF-7 300 14 367 7 
BT474 336 9 376 3 
Flow cytometric analysis of cells from spheroid co-cultures and paraffin sections  
of spheroids derived from the five different breast tumor cell lines co-cultured for 40 h with 
peripheral blood MO showed, that MO to breast tumor cell ratios differ between individual 
cell lines (Tab. 3.3, Fig. 3.3 and Fig. 3.4). MO migrated most effectively into Hs578T breast 
cancer cell line spheroids, T47D spheroid infiltration by MO was intermediate and BT549, 
MCF-7 and BT474 were poorly infiltrated. Because of massive MO migration into Hs578T, 
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these co-culture were further studied in more detail, e.g. with respect to MO migration 
kinetics. 
Tab. 3.3 Mean proportion of cells (MO and tumor cells) in spheroid co-cultures 40 h after 
addition of MO. 
 
Percentage of monocytes 
in co-culture (%) 
Breast tumor cell line MO (%) T (%) SD 
Hs578T 48.3 51.7 5.1 
T47D 18.6 81.4 1.3 
BT549 8.4 91.6 2.6 
MCF-7 3.8 96.2 3.8 
BT474 1.3 98.7 1.0 
 
100 µm
 
Fig. 3.3 Representative stained paraffin section (4 µm) through the center of spheroids 
consisting of various tumor cells and MO co-cultured for 40 h. The sections were stained for 
monocytes marker CD45 using ABC/DAB method for detection; counterstained with 
hematoxilin. Cell lines: (a) BT474; (b) BT549; (c) Hs578; (d) MCF-7; (e) T47D. 
Bar = 100 µm applies to all parts a-e. MO are stained brown. 
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Fig. 3.4 MO to breast tumor cell ratio in spheroid co-cultures with Hs578T, T47D, BT549, MCF-
7, BT474 cell lines. The ratio of a mixed cell suspension isolated from tumor spheroids (40 h 
co-culturing, 1x104 MO/spheroid) was determined using flow cytometry. Cells were stained 
with APC-conjugated CD45 antibody. (a) Representative dot plot diagram showing FL-4 
fluorescence versus 90° scatter signals, (b) Column s in graphs show averaged mean values 
and SD of three independent experiments with MO from 3 different healthy donors. 
 
To determine the minimal time for successful and reproducible MO and Hs578T  
co-culturing, the MO migration kinetics into Hs578T spheroids was analyzed by determining 
the tumor cell to MO ratios after 4, 10, 20 and 40 h in co-culture. Fig. 3.5 shows that the MO 
infiltration process is completed within 10 h, and slower than into fibroblast spheroids  
(4 h, Fig. 3.1). Hence, the 10 h co-culturing was chosen as optimal for all further 
experiments with Hs578T spheroids. 
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Fig. 3.5 Monocyte migration into Hs578T breast tumor cell line spheroids is completed within 
10 h. MO to breast tumor cell line proportion in Hs578T spheroid co-culture was checked 4, 
10, 20 and 40 h after addition of 1x104 MO per spheroid. The cell ratio (± SD) was determined 
using flow cytometry following spheroid dissociation and staining with monocyte specific  
APC-conjugated anti-CD45 antibody. Columns in graphs show mean values and SD of three 
independent experiments with MO from 3 different healthy donors. 
3.1.3 Migrating MO population 
Flow cytometric analysis of co-cultures consisting of MO and fibroblasts or MO and tumor 
cells described in chapters 3.2.1 and 3.2.2 allowed to determine the cell ratio (F or tumor 
cell to MO) in spheroids. However, since the total cell number differed for each spheroid 
type at the day of analysis and depended on the growth characteristics of the individual cell 
type, the number of infiltrated MO was calculated from the data and the proportion  
of migrated blood MO relative to the number of MO applied per spheroid (1x104) was 
estimated. The results summarized in Tab. 3.3 and 3.4 show that migrating MO population 
is not equal with percentage of MO in spheroid. For Hs578T cells, for example, mean 
proportion of MO equals 48.3% of spheroid co-culture and size of migrating MO 
subpopulation equals 25.9%, PF27T-MO co-cultures consist in 54.5% from MO (Tab. 3.1), 
however migrating MO subpopulation is smaller than for Hs578T cells and equals 14.8%. 
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Tab. 3.4 Proportion of blood MO that migrated into tumor cell line spheroids or spheroids of 
tumor-derived fibroblasts (co-culture time: 40 h for tumor cell line spheroids, 4 h for 
fibroblast spheroids). 
 Migrating MO 
subpopulation (%) 
Breast tumor cell line average SD 
Hs578T 25.9 3.6 
T47D 8.9 1.2 
BT549 2.7 0.8 
MCF-7 1.1 1.0 
BT474 0.6 0.5 
TAF average SD 
PF27T 14.8 2.2 
PF37T 11.7 1.1 
PF53T 17.9 0.8 
3.2 Experiments to verify the role of chemokines (CCL2) in MO 
migration into spheroids  
3.2.1 CCL2 release from spheroids of breast tumor origin 
CCL2 release of breast tumor spheroids was measured and compared to that released 
from TAF spheroids. Supernatants were collected 96 h after cell inoculation in liquid overlay 
to reflect the CCL2 concentration at the onset of co-culturing. Also cell number at this time 
point was checked and is given in Tab. 3.5. Chemokine level was checked via ELISA and 
release rates were calculated per cell and are presented in Fig. 3.6 and Tab. 3.6. 
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Tab. 3.5 Cell number calculated per spheroid 96 h after cell inoculation in liquid overlay. 
 
Cell number pro spheroid 
Breast tumor cell line average SD 
Hs578T 3211 455 
T47D 3848 339 
BT549 3550 410 
MCF-7 2293 256 
BT474 3632 565 
Hs578T T47D BT549 MCF-7 BT474
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Fig. 3.6 CCL2 level and cellular release rates differs between five breast tumor cell lines in 
spheroid culture. CCL2 release was determined by ELISA and calculated in pg/cell. 
The data summed up in Tab. 3.6 reveal that MO strongly infiltrate those cell lines which 
express relative high amounts of CCL2. Cell lines which do not produce CCL2 or at much 
lower levels were poorly infiltrated by MO. However, the mean proportion of MO to tumor 
cells does not simply increase with CCL2 level. In general, four of five tumor spheroid 
types, show a lower infiltration by MO than tumor-derived spheroids. MO infiltration rates 
reach about 50% which can be compared with that for TAF spheroids only in the Hs578T 
tumor spheroid type. 
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Tab. 3.6 Release rate of CCL2 protein for breast tumor cell lines, calculated pro one cell and 
mean ratio of MO that migrated into tumor cell line spheroids. 
 CCL2 release (pg/cell) Percentage of MO 
In c-culture (%) 
Breast tumor cell line average SD average SD 
Hs578T 50.7x10-3 0.6x10-3 48.3 5.1 
T47D 3.4x10-3 1.5x10-3 18.6 1.3 
BT549 21x10-3 6.1x10-3 8.4 2.6 
MCF-7 0 0 3.8 3.8 
BT474 0.2x10-3 0.2x10-3 1.3 1.0 
3.2.2 Exogenous modulation of the paracrine milieu (of fibroblast spheroids)  
3.2.2.1 Wash-out approaches 
The paracrine factors released by fibroblasts can influence spheroid infiltration by MO.  
To evaluate their impact on MO migration, level of paracrine factors (including CCL2) was 
reduced by washing out of supernatant and replacing it with new, unconditioned medium. 
The conditioned medium from the milieu of spheroids seeded in 96 well plates, was 
removed (90%) just before addition of the MO suspension (1x104 MO per spheroid), as 
described in chapter 2.2.1.2. In parallel, control experiments without medium replacement 
was conducted. Both “wash out” and unchanged samples were checked for CCL2 release 
(ELISA) and MO infiltration (FC) after 2, 4, 6, 8 and 20 h of co-culturing (Fig. 3.7a and b, 
respectively). 
As shown in Fig. 3.7.a, CCL2 level is high (5959±351 pg/ml) at the onset of co-culturing but 
does not significantly increase over a period of 20 h. CCL2 level in “wash out” samples  
is reduced to about 20% of the control spheroids but then accumulates slowly. After 20 h, 
CCL2 level has reached 80% of the control values. 
Removing of paracrine factors in “wash out” samples, significantly delayed (p<0.05) 
migration kinetics of MO into “wash out” fibroblast spheroids relative to control spheroids 
which is reflected by a lower number of migrated MO after 4 h and 6 h of co-culturing as 
documented in Fig. 3.7b. 
Results  57 
 
2h
 control
2h
 wash
 out
4h
 control
4h
 wash
 out
6h
 control
6h
 wash
 out
8h
 control
8h
 wash
 out
20h
 control
20h
 wash
 out
0
20
40
60
80
100
ce
lls
 
in
 
co
-
cu
ltu
re
 
(%
)
 MO
 F
2h
 control
2h
 wash
 out
4h
 control
4h
 wash
 out
6h
 control
6h
 wash
 out
8h
 control
8h
 wash
 out
20h
 control
20h
 wash
 out
0
1000
2000
3000
4000
5000
6000
7000
8000
CC
L2
 
co
n
ce
n
tr
at
io
n
 
(p
g/
m
l)
b)
a)
*
*
*
*
*
*
ce
lls
 
in
 
co
-
cu
ltu
re
 
(%
)
CC
L2
 
co
n
ce
n
tr
at
io
n
 
(p
g/
m
l)
 
Fig. 3.7 “Wash out” of paracrine factors from external milieu of TAF spheroids results in 
delayed MO migration. (a) CCL2 concentration was determined as a representative paracrine 
factor of interest by ELISA. In “wash out” samples after 2, 4, 6, 8 h CCL2 is reduced as 
compared to control supernatants, the difference is significant (p<0.05). CCL2 concentration 
increases as a function of time in culture to reach the level in control wells with fibroblast 
spheroids after 20 h of co-culturing. (b) Removing of paracrine factors through “wash out” 
delays migration kinetics of MO into fibroblast spheroids relative to control for 4 h and 6 h of 
co-culturing, the difference is significant (p<0.05). Columns in graphs show mean values and 
SD of three independent experiments with MO from 3 different healthy donors. 
* Significance level: p< 0.05 
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3.2.2.2 Addition of CCL2 
According to the hypothesis, that high release of CCL2 by TAF can be responsible for 
enhanced MO migration into tumor-derived fibroblast spheroids, experiments were 
performed to alter the gradient of CCL2. If there is a gradient within the fibroblast spheroids, 
supplementation of the exogenous milieu with high levels of rhCCL2 should invert the 
gradient of this protein with respect to intra- and extraspheroidal distribution  
as schematically shown in Fig. 3.8. 
The addition of rhCCL2 at a concentration of 0.02 µg/ml (10x) reduced MO migration into 
TAF (PF53T) spheroids by about 50%. When the extraspheroidal CCL2 concentration was 
increased by addition of 100x the amount released by the tumor-derived fibroblast 
spheroids, MO migration decreased to 5% of the control level (Fig. 3.9). This observation 
was revealed in three independent experiments, i.e. with MO from three healthy donors. 
Normal fibroblasts produce significantly less CCL2 than breast tumor-derived fibroblasts. 
MO migration to spheroids originated from normal tissue is also significantly lower (Silzle et 
al., 2003). To find out if MO migration into normal fibroblast spheroids may also depends on 
CCL2 gradient an analogue experimental series as these explained in Fig. 3.8, was 
performed. In this set of experiments, normal foreskin fibroblasts VF1 that have low CCL2 
release and MO infiltration rates were used. The concentration of added CCL2 was adopted 
in order to obtain an external milieu enriched in CCL2 by a factor of 10 (0.002 µg/ml) and 
100 (0.02 µg/ml) relative to control. As shown at Figure 3.10, MO migration is unaltered  
by exogenous rhCCL2, indicating that CCL2 is not responsible for the basic, non-tumor-
associated MO migration into normal fibroblast spheroids. 
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Fig.3.8. Conditions to affect MO migration by the addition of exogenous rhCCL2. (a) control 
without supernatant supplementation, (b) supernatant supplemented with 10x higher 
concentration of CCL2 than released by tumor derived fibroblasts spheroids, (c) supernatant 
supplemented with 100x higher concentration of CCL2 than released by TAF spheroids. 
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Fig. 3.9 MO migration into tumor-derived fibroblast spheroids is reduced by the addition of 
rhCCL2 to the supernatant and loss of the CCL2 gradient under standard culture conditions. 
(a) Representative dot plot diagrams and proportion (± SD) of fibroblasts and MO in spheroid 
co-cultures 4 h after addition of 1x104 MO/well and per spheroid. Dot plot diagrams show FL-1 
fluorescence versus 90° scatter signals of a mixed cell suspension isolated from PF53T 
spheroids. The cell suspension was stained with the FITC-conjugated ‘fibroblasts specific’ 
antibody AS02. (b) Columns in graphs show averaged mean values and SD of three 
independent experiments with  MO from 3 different healthy donors. 
* Significance level: p< 0.05 
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Fig. 3.10 MO migration into normal foreskin fibroblast (VF1) spheroids is not influenced by 
the addition of rhCCL2 to the supernatant and loss of the CCL2 gradient under standard 
culture conditions. (a) Representative dot plot diagram and proportion (± SD) of fibroblasts 
and MO in spheroid co-cultures 4 h after addition of 1x104 MO/well and per spheroid. Dot plot 
diagrams show FL-1 fluorescence versus 90° scatter signals of a mixed cell suspension 
isolated from VF1 spheroids. The cell suspension was stained with FITC-conjugated 
‘fibroblasts specific’ antibody AS02. (b) Columns in graphs show averaged mean values and 
SD of three independent experiments with MO from 3 different healthy donors. 
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3.2.3 Experimental approaches to modulate cellular CCL2 release from fibroblast 
spheroids by siRNA 
The RNAi method was considered to down regulate CCL2 levels in breast-tumor-derived 
fibroblasts spheroids as an alternative to neutralization of endogenous CCL2 by a blocking 
antibody, which did not achieved the expected results. Application of siRNA, if successful, 
would allow further mechanistic studies on MO migration and the comparison of MO 
migration activity with endogenous CCL2 production when significantly reduced. 
According to the standard procedure, at day 4 after transfection, cells grown in monolayer 
were harvested and seeded again in liquid overlay for spheroid initiation and as monolayer. 
Routinely for dissociation a trypsin/EDTA in PBS solution is used. To control the potential 
influence of dissociation means on CCL2 reduction, other enzymes were also tested: 
collagenase III and accutase. The collagenase III induced cell death, trypsin/EDTA and 
accutase neither influenced viability of cells nor the siRNA effect in monolayer relative to 
non-transferred cells. Trypsin/EDTA, as commonly used reagent, was chosen for all further 
experiments.  
Breast-tumor-derived fibroblasts (PF27T) were transfected with use of self-designed 
siRNAs (ds1 + ds2) using oligofectamine. The amount of CCL2 was checked at protein 
level via ELISA. Protein level, both for 2-D and 3-D cultures was compared at day 7 after 
transfection and cellular release was monitored for a 24 h (monolayer) or 72 h (spheroid) 
time intervals. However, the desired effect of down-regulation (>80%) of CCL2 protein was 
achieved only for monolayer (2-D) cultures. The CCL2 release in spheroid cultures (3-D)  
as determined in the supernatant was unaltered (Fig. 3.11). 
Results  63 
 
dcontrold7
ds1+ds2
 d7
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
CC
L2
 
re
le
as
e
(pg
/c
el
l)
controld4
ds1+ds2
 d4
CC
L2
 
re
le
as
e
(
)
2-D culture 3-D culture
control d7
ds1+ds2
 d7
c
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
CC
L2
 
re
le
as
e
(pg
/c
el
l)
a) b)
CC
L2
 
re
le
as
e
(pg
/c
el
l)
**
CC
L2
 
re
le
as
e
(pg
/c
el
l)
CC
L2
 
re
le
as
e
(
)
CC
L2
 
re
le
as
e
(pg
/c
el
l)
CC
L2
 
re
le
as
e
(pg
/c
el
l)
CC
L2
 
re
le
as
e
(pg
/c
el
l)
CC
L2
 
re
le
as
e
(
)
CC
L2
 
re
le
as
e
(pg
/c
el
l)
CC
L2
 
re
le
as
e
(pg
/c
el
l)
 
Fig. 3.11 Transfection of fibroblasts with CCL2 specific siRNA results in reduced release of 
CCL2 protein from cells in 2-D but not 3-D culture. (a) Graph shows the 24 h cellular release 
rate of CCL2 measured in supernatants with ELISA (calculated in pg/cell) at days 4 and 7 
(respectively: d4, d7) after transfection of PF27T fibroblasts. CCL2 protein expression is 
down regulated at days 4 and 7 after transfection. (b) In 3-D cultures, 7 days after transfection 
no reduction on protein level is observed; here, the 72 h CCL2 release was measured. PF27T 
fibroblasts were transfected with self-designed siRNAs (ds1+ds2) and transferred at day 4 
after transfection using mild enzymatic means. Control cells were transfected with non-
specific control siRNA. Columns in graphs show averaged mean values and SD of three 
independent experiments. 
* Significance level: p< 0.05 
In order to verify that the discrepancy between monolayer (2-D) and spheroid (3-D) culture 
with respect to the siRNA efficiency is independent of the fibroblast type, a second batch  
of tumor-derived fibroblasts (PF53T) was applied in an identical experimental setting.  
Fig. 3.12 shows that the results are consistent with those obtained for PF27T. For 
monolayer (2-D culture) down-regulation of cellular CCL2 protein release of about 80% was 
obtained. The CCL2 release from spheroid cells (3-D culture) measured in the supernatant 
was unchanged by the siRNA approach. 
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Fig. 3.12 Transfection of fibroblasts with CCL2 specific siRNA results in reduced release of 
CCL2 protein from cells in 2-D but not 3-D culture. (a) Graph shows the 24 h cellular release 
rate of CCL2 measured in supernatants with ELISA (calculated in pg/cell) at days 4 and 7 
(respectively: d4, d7) after transfection of PF53T fibroblasts. The 24 h release rate of CCL2 
expression, measured with ELISA and calculated in pg/cell, is down regulated at days 4 and 7 
after transfection. (b) In 3-D cultures, 7 days after transfection no reduction on protein level is 
observed; here, the 72 h of CCL2 release was measured. PF53T fibroblasts were transfected 
with self-designed siRNAs (ds1+ds2) and transferred at day 4 after transfection using mild 
enzymatic means. Control cells were transfected with non-specific control siRNA. Columns in 
graphs show averaged mean values and SD of three independent experiments. 
* Significance level: p< 0.05 
While the experiments with self designed siRNA were in progress, a CCL2 specific siRNA 
became commercially available. Experiments with this siRNA  from Ambion (Silencer 
siRNA) were performed according to the same scheme as for self designed siRNA, and the 
down regulating effects were compared. As shown in Fig. 3.13, the results were 
comparable to those achieved in experiments with self-designed siRNAs (ds1 + ds2). The 
data imply that CCL2 expression is on longer down-regulated after transfer of cells into a 3-
D culture format. This cannot be due to extended culturing since CCL2 protein release was 
measured at day 7 after siRNA transfection in both culture settings (2-D and 3-D).  
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Fig. 3.13 Transfection of PF27T fibroblasts with Silencer siRNA in 2-D culture reduces CCL2 
on protein level. There is no difference in transfection efficiency between self designed 
siRNAs (ds1+ds2) and commercially available Silencer siRNA. (a) The 24 h CCL2 release rate 
was measured (ELISA) and calculated in pg/cell. Columns show mean values (± SD) of three 
independent experiments. The reduction is significant (p<0.05). (b) Columns show reduction 
of CCL2 in 2-D culture when transfected with either self-designed (ds1+ds2) or commercially 
available CCL2 specific siRNA as compared to control. At day 7 after transfection significant 
reduction in CCL2 release is observed. The 24 h release rate of CCL2 was measured in 
supernatant with ELISA and calculated relative to cell numbers in pg/cell. In 3-D cultures no 
or insufficient CCL2 protein reduction versus control is obtained. A single experiment was 
performed as it revealed in past the data presented in Fig. 3.12. 
* Significance level: p< 0.05 
The aim of the next set of experiments was to clarify, if siRNA is still present in transfected 
cells when grown in a 3-D culture setting in spite of loss of down-regulation of CCL2 protein 
release. The experiments were performed according to the described scheme but included 
an additional fluorescently labeled negative control siRNA (Alexa Fluor488). 
CCL2 level in monolayers was again successfully reduced. In 3-D cultures no reduction 
was observed (Fig. 3.15.a) as shown earlier. Invert fluorescence microscopy enabled the 
visualization of Alexa Fluor488-conjugated control siRNA in the cells (Fig.3.15.b). 
Additionally, confocal microscopy was used to verify that more than just the outer layer  
of spheroid cell is fluorescently labeled and thus contained siRNA at the onset of spheroid 
culturing. In summary, the technological tools applied, indicate that siRNA transfection  
in principle has been successful (Fig.3.15.c) and that siRNA was present at least when 
spheroids were initiated. 
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Fig. 3.15 (a) PF53T fibroblasts were transfected with CCL2 specific siRNA ds1 + ds2 in 
parallel to a fluorescently labeled negative control siRNA. As shown earlier, reduction of 
CCL2 protein level in 2-D cultures after applying ds1+ds2 siRNA measured with ELISA was 
significant (p<005). In 3-D cultures no significant reduction was measured. Columns show 
mean values and SD of three independent experiments. (b) PF53T fibroblasts transfected with 
control siRNA Alexa Fluor488 are fluorescently labeled in 2-D and 3-D culture. Microscopic 
images: 1) phase contrast image of 2-D culture, 2) fluorescence image of 2-D culture, 3) phase 
contrast image of 3-D culture, 4) fluorescence image of 3-D culture. The fluorescent dye 
(bound to siRNA) is still visible at day 7 after transfection both in monolayer and in spheroid 
cultures. For images 1 and 2 magnification of 20 x objective was used, images 3 and 4 were 
taken with a 10 x objective. (c) PF53T fibroblasts transfected with Alexa Fluor488-conjugated 
control siRNA. 3-D culture was monitored by  confocal microscope. A Z-stack of 5 µm 
sections was recorded with a magnification of 10 x objective. 
* Significance level: p< 0.05 
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The last set of experiments was performed to verify the differences in reduction of CCL2 
protein release on the RNA level and thus to gain insight into the discrepancy between 
CCL2 regulation in 2-D vs. 3-D culture. Experiments were performed according to the 
standard protocol described in chapter 2.2.5.5. At day 7 after transfection RNA was isolated 
from cells cultured as monolayer and as spheroids. To verify quantity of isolated nucleic 
acid, RNA was converted into cDNA and Real-Time-PCR was performed. Supernatants 
used for the parallel analysis of CCL2 release rates confirmed previous outcomes. In 2-D 
cultures reduction of CCL2 RNA expression in cells transfected with ds1+ds2 siRNA  
as compared to control cells was observed. In 3-D cultures, however, RNA level was 
increased in samples transfected with ds1+ds2 siRNA (Fig. 3.16). Thus, the CCL2 protein 
levels corresponded to a reduced mRNA level in 2-D culture while in 3-D culture which 
lacked siRNA-related CCL2 protein reduction mRNA level was enhanced relative to control. 
It is unclear why the highly efficient silencing RNA in 2-D culture looses its efficacy in 3-D 
culture. Understanding this phenomenon was beyond the scope of the present work and 
the siRNA approach was therefore terminated at this point. 
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Fig. 3.16 Transfection of PF37T fibroblasts with self-designed siRNA (ds1+ds2), in two 
independent experiments significantly reduced CCL2 protein release and RNA expression at 
day 7 after transfection in 2-D (left panels) but not 3-D culture (right panels) (p<005). Protein 
level was measured with ELISA and calculated in pg/cell. CCL2  RNA expression was 
reproducibly up regulated in 3-D cultures after transfection of monolayer cells with 
CCL2specific siRNA. 
* Significance level: p< 0.05 
3.2.4 Blockade of chemokine signaling pathways 
3.2.4.1 Application of toxins 
All chemokines signal through interaction with 7-transmembrane spanning G protein 
coupled receptors. Pertussis toxin (PTX) is known to block signal pathways for some 
chemokines through its interaction with Gαi/o proteins. One of the receptors sensitive  
to PTX is the receptor for CCL2 – CCR2A/B (Combadiere et al., 1998). PTX B-oligomer 
was used as negative control as it binds toxin to the target but has no  
ADP-ribosyltransferase activity to efficiently block signaling (Tamura et al., 1982; Katada et 
al., 1983). 
MO were incubated with PTX or with PTX B-oligomer in concentrations of 1, 10 and  
50 ng/ml for 30 min prior to addition to breast tumor-derived fibroblast spheroids and during 
co-culturing time. Their migration activity was monitored and compared with control MO 
(untreated). Flow cytometric analyses were performed after 4 h. 
Incubation of MO with PTX blocked the migration of MO into spheroids for all applied 
concentrations of toxin. MO migration was critically reduced already with the lowest toxin 
concentration where the B-oligomer showed no effect (see Fig. 3.17). At high 
concentrations B-oligomer also affected MO migratory activity but the effect never reached 
a grade similar to PTX holoenzyme. The observed effect may be explained by the presence 
of holotoxin (≤1%) in the B-oligomer preparation as discussed later. The data clearly 
demonstrate that blockade of Gαi/o dependent signaling abrogates MO migratory activity  
in the 3-D culture model. 
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Fig. 3.17 PTX blocks MO migration (p<005). PTX B-oligomer shows weak blocking effect on 
MO migratory activity only at the highest concentration (50 ng/ml). (a) Representative dot plot 
diagrams and proportion (± SD) of fibroblasts (F) and MO in spheroid co-cultures 4 h after 
addition of 1x104 pretreated MO/well and per spheroid, respectively. Diagrams show FL-1 
fluorescence versus 90° scatter signals in a dissoc iated cell suspension from PF37T - MO  
co-cultures. The cell suspension was stained with the FITC-conjugated ‘fibroblasts specific’ 
antibody AS02. MO pre-treatment was performed with 1, 10 or 50 ng/ml B-oligomer or PTX for 
30 min at 37°C. (b) Columns in graph show averaged mean values and SD of three 
independent experiments according to (a) with MO from 3 different healthy donors. 
* Significance level: p< 0.05 
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To find out if the inhibition of MO migration is specific for PTX and Gαi/o dependent 
pathways, a set of experiments was performed using cholera toxin (ChTX). This toxin can 
block Gαs proteins in their active form but does not interfere with Gαi/o (Chang and Bourne, 
1989). Similar to the previous experimental series, MO were incubated with ChTX 
holoenzyme or with ChTX B-subunit which only possesses binding property but should not 
block Gαs (Fishman, 1982). 
Both ChTX holoenzyme and B-subunit were applied in the following concentrations:  
1 ng/ml, 10 ng/ml and 50 ng/ml. MO were exposed to toxins 30 min prior to addition to  
F spheroids and during co-culturing time. MO migration activity was monitored and 
compared with control MO (untreated). Flow cytometric analyses were performed after 4 h. 
The 1 ng/ml to 50 ng/ml concentrations were applied in three independent experiments with 
MO from three healthy donors and these results are shown in Fig. 3.18. The B-subunit did 
not affect MO migration activity at any concentration. However, the ChTX holoenzyme led 
to a significant and reproducible reduction in MO migration at concentrations of 10 ng/ml 
and 50 ng/ml. The concentration of ChTX required for significantly affecting MO infiltrative 
activity was thus by a factor of ≥10 higher than for PTX. 
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Fig. 3.18 ChTX at concentrations of 10 and 50 ng/ml lead to a significant reduction of MO 
migration (p<005) . ChTX B-subunit shows no blocking effect on MO migratory activity. (a) 
Representative dot plot diagrams and proportion (± SD) of fibroblast (F) and MO in spheroid 
co-cultures 4 h after addition of 1x104 pretreated MO/well and per spheroid, respectively. 
Diagrams show FL-1 fluorescence versus 90° scatter signals in a dissociated cell suspension 
from PF37T-MO co-cultures. The cell suspension was stained with FITC-conjugated 
‘fibroblasts specific’ antibody AS02. MO pre-treatment was performed with 1, 10 or 50 ng/ml 
B-subunit or ChTX for 30 min at 37°C. (b) Columns i n graph show averaged mean values and 
SD of three independent experiments according to (a) with MO from 3 different healthy 
donors. 
* Significance level: p< 0.05 
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3.2.4.2 Application of blocking antibodies 
3.2.4.2.1 Studies with fibroblast spheroids 
Experiment with PTX revealed a high relevance of Gαi/o protein mediated pathways for MO 
migration into spheroids of breast tumor-derived fibroblasts. From all previous data it was 
again hypothesized that the CCL2/CCR2A/B pathway is the critical determinant for MO 
migration in the present experimental 3-D culture system. DOC-3 blocks supposedly 
CCR2A/B receptor on MO (M. Mack - personal communication). To answer the question, if 
exclusive blockade of CCR2A/B is sufficient to reduce MO infiltration to levels described for 
normal fibroblast spheroids, DOC-3 was applied in this set of experiments. 
DOC-3 (kindly provided by Prof. Matthias Mack; University of Regensburg, Germany) were 
applied in two concentrations: 1µg/ml and 10 µg/ml. The concentration of 1 µg/ml blocked 
MO migration only to some degree, thus finally concentration of antibody 10 µg/ml was 
chosen for experiments. Thus, MO were incubated with DOC-3 or with corresponding 
isotype (IgG1) 30 min prior to TAF spheroids and during co-culturing. Co-cultures were 
collected after 20 h and dissociated for flow cytometric analyses. The results clearly show 
that migration of MO after incubation with blocking Ab at the given concentrations 
significantly decreased the mean proportion of MO in fibroblast co-cultures from 53± 14%  
to 13±8% (Fig. 3.19). 
To show that the inhibitory effect of DOC-3 antibody is not artificially caused by the MO 
exposure to a specific antibody, experiments with blocking Ab against CD11b were 
performed. According to the experimental series with DOC-3, MO were pre-incubated either 
30 min with anti-CD11b Ab at a concentration of 10 µg/ml or with a corresponding isotype 
control (IgG2a) and then added to TAF spheroids. Co-cultures were also exposed to the Ab 
and were collected after 20 h for dissociation and flow cytometric analysis of fibroblast  
to MO ratio. No blocking effect of anti-CD11b Ab was observed (Fig. 3.20). 
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Fig. 3.19 CCR2A/B blockade on MO by DOC-3 antibody significantly reduced MO migration 
into tumor-derived fibroblast spheroids (p<005). Isotype control IgG1 had no effect on MO 
migration. (a) Representative dot plot diagrams and proportion (± SD) of fibroblasts (F) and 
MO in spheroid co-cultures 20 h after addition of 1x104  pre-treated MO/well and per spheroid, 
respectively. Diagrams show FL-1 fluorescence versus 90° scatter signals in a dissociated 
cell suspensions from PF37T-MO co-cultures. The cell suspension was stained with FITC-
conjugated ‘fibroblasts specific’ antibody AS02; MO pre-treatment was performed with 10 
µg/ml DOC-3 or isotype IgG1 for 30 min at 37°C. (b) Columns in graphs show averaged mean 
values and SD of three independent experiments according to (a) with MO from 3 different 
healthy donors. 
* Significance level: p< 0.05 
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Fig. 3.20 Anti-CD11b antibody does not influence MO migration. (a) Representative dot plot 
diagrams and proportion (± SD) of fibroblasts (F) and MO in spheroid co-cultures 20 h after 
addition of 1x104 pretreated MO/well and per spheroid, respectively. Diagrams show FL-1 
fluorescence versus 90° scatter signals in a dissoc iated cell suspension from PF53T-MO co-
cultures. The cell suspension was stained with FITC-conjugated ‘fibroblasts specific’ 
antibody AS02; MO pre-treatment was performed with 10 µg/ml CD11b or isotype IgG2a for 30 
min at 37°C. (b) Columns in graph show averaged mea n values and SD of three independent 
experiments according to (a) with MO from 3 different healthy donors. 
3.2.4.2.2 Studies with breast tumor cell line spheroids 
Hs578T spheroids were characterized by high release of CCL2 and pronounced infiltration 
by MO. Since CCR2A/B blockade efficiently inhibited MO migration into tumor-derived 
fibroblast spheroids, it was hypothesized that the same approach blocks Hs578T infiltration 
by MO. 
MO were pre-incubated with DOC-3 or with corresponding isotype (IgG1) for 30 min and 
than added to Hs578T 3-D cultures. Co-cultures were also exposed to the Ab and were 
collected after 40 h and dissociated for flow cytometric analyses. The data documented  
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in Fig. 3.21 clearly show that MO migration into Hs578T was unaffected by CCR2A/B 
blockade. According to previous studies this observation was reproduced in 3 independent 
experiments, i. e. with MO from 3 different donors.  
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Fig. 3.21 DOC-3 exposure and CCR2A/B blockade had no effect on MO migration into Hs578T 
spheroids. (a) Representative dot plot diagram and proportion (±SD) of Hs578T tumor cells 
and MO in spheroids co-cultures 40 h after addition of 1x104 pretreated MO/well and per 
spheroid, respectively. Diagrams show FL-4 fluorescence versus 90° scatter signals in a 
dissociated cell suspension from Hs578T-MO co-cultures. The cell suspension was stained 
with APC-conjugated monocytes specific CD45 antibody; MO pre-treatment was performed 
with 10 µg/ml DOC-3 or isotype IgG1 for 30 min at 37°C. (b) Columns in graph show averaged 
mean values and SD of three independent experiments according to (a) with MO from 3 
different healthy donors. 
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3.3 Experiments to identify the migrating blood MO 
subpopulation 
The results obtained by Silzle et al. (Silzle et al., 2003) imply a relatively constant 
subpopulation of blood MO capable of infiltrating tumor-derived/associated fibroblasts (TAF) 
spheroids. This was verified in the present study. The TAF spheroids used in presented 
thesis (PF27T, PF53T, PF37T) were reproducibly infiltrated by a blood MO population 
between 10% and 20% (see Tab. 3.4, chapter 3.1.3). Several experiments were designed 
to identify the potential migrating blood MO population 
3.3.1 Flow cytometric analysis of monocyte subpopulations 
3.3.1.1 Expression of CCR2A/B 
The experiments with the CCR2A/B blocking antibody DOC-3 implies a role of CCL2 in the 
MO migrating process into TAF but not tumor cell spheroids. The receptor for CCL2, 
CCR2A/B, on MO surface was stained with the DOC-3 antibody and a FITC-conjugated 
secondary antibody labeled in order to find out if there is a MO subpopulation with distinct 
expression of CCR2A/B receptor. The staining showed that roughly all MO express the 
receptor (Fig. 3.22) indicating that there is no difference in CCR2A/2B expression between 
migrating and non-migrating MO.  
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Fig. 3.22 No 10%-20% MO subpopulation was identified by the CCR2A/B expression profile. 
Figure show representative overlay histogram of the blood MO isolated from a healthy donor 
by counter-current centrifugal elutriation, stained with DOC-3 primary antibody (green) or 
isotype control (white) and a FITC-conjugated secondary antibody. 
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3.3.1.2 CD14/CD49e/CD11a or CD11b expression 
According to MO surface expression profiles described in the literature, the following 
multicolor stainings were established for flow cytometric analysis of surface antigen 
expression: CD14/CD49e/CD11a and CD14/CD49e/CD11b. CD11a and CD11b are  
α subunits of two β integrins LFA-1 (Lymphocyte Function Associated Antigen-1) and  
MAC-1 (Macrophage Antigen-1), respectively. CD49e form with CD29 α-integrin called  
VLA-5 (Very Late Antigen-5). CD14 is LPS receptor, expressed on MO in different level. 
Flow cytometric analyses of freshly isolated MO do not indicate a MO subpopulation  
of about 10-20% with a selective expression profile for the markers of interest as 
documented in Fig. 3.23. 
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Fig. 3.23 No 10%-20% subpopulation can be identified by the expression of the surface 
antigens CD14,CD49e, CD11a and CD11b which could relate to or reflect a high infiltrative MO 
population. Representative dot plot diagrams shows expression of: (a) CD14, CD49e, CD11a, 
(b) CD14, CD49e, CD11b antigens on the surface of blood MO isolated by counter current 
centrifugal elutriation. 
3.3.2 Migration of isolated MO subpopulations into fibroblast spheroids 
It was reported in the literature that blood MO subpopulation can be differentiated by the 
antigens CD14 and CD16 and that particular CD14/CD16 subpopulations are characterized 
by enhanced migratory activity (Weber et al., 2000). These subpopulations could indeed be 
identified by flow cytometric analyses. Gates (regions of interest) were defined to sort 
different fractions of MO for subsequent co-culturing experiments as shown in  Fig. 3.24.  
In three independent experiments i.e. MO from three different donors were isolated 
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according to their expression profile via fluorescence-activated cell sorting and added  
to TAF spheroids with a concentration of 1x104 MO per spheroid according to previous 
experiments. Migration potential of isolated MO subpopulations was analyzed by 
determining the F to MO ratio after 4 h of co-culturing. The results summarized in Tab. 3.7 
show that all of these subpopulations infiltrate TAF spheroids with a similar potential. 
Tab. 3.7 Migration of MO into spheroids of tumor-derived fibroblast spheroids. MO fractions 
were sorted according to their CD14/CD16 expression as representatively shown in Fig. 3.24 
and added with a concentration of 1x104/spheroid. 
MO  
added to  
fibroblast spheroids 
Percentage of cells in co-culture 
and SD (%) 
MO F SD 
Control MO unstained* 57.35 42.65 15.07 
stained (CD14+CD16-)** 57.98 42.02 16.83 
stained + run through 
sorter*** 
58.41 41.59 3.7 
Stained 
and run 
through 
sorter 
MO fractions 
CD14++CD16- 60.08 39.92 3.69 
CD14+CD16++ 53.83 46.17 5.59 
CD14++CD16++ 54.12 45.88 9.03 
CD14++CD16+ 50.44 49.56 15.22 
*    Unstained control – untreated MO, whole blood MO population was added to F spheroids. 
**  Stained control – MO were stained with CD14 and CD16 antibody, stained whole blood MO 
population were added to F spheroids. 
*** Stained + run through sorter control - MO were stained with CD14 and CD16 antibody and 
run through sorter, after this treatment whole blood MO population were added to fibroblast 
spheroids. 
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3.3.3 Isolation and expression profiling of migrated versus non-migrated MO 
Since the search for surface antigens which could specify particular migrating blood MO did 
not result in the identification of characteristic subpopulation, a new approach was 
designed. The goal of the initial experimental series was to compare gene expression 
profiles in migrating and non-migrating MO using cDNA arrays. MO were co-cultured with 
TAF spheroids for 4 h (the minimal time required to complete MO migration) and then 
separated as described in chapter 2.2.5.2. The experiment was performed in triplicate. 
cDNA arrays were performed using RNA from fallowing samples: MO which migrated into 
spheroids and were subsequently separated from fibroblasts (MO inside); MO which during 
incubation time stayed outside spheroids and did not migrated (MO outside) and controls: 
MO kept 4 h at 4°C (C1) and MO kept 4 h in Teflon b ags at 37°C (C2) (see Tab. 2.15, 
chapter 2.2.7.4.2). Gene expression profiles differed significantly between migrated MO 
(MO inside) and non-migrated MO (MO outside) as shown at Fig. 3.25. No difference is 
seen between control samples (C1 and C2) and non-migrated MO. 
Fig. 3.24. Representative dot plot 
diagram shows expression of 
CD14 and CD16 antigens on 
monocyte surfaces. Several 
fractions were gated for sorting: 
R1 – CD14++CD16- 
R2 – CD14+CD16++ 
R3 – CD14++CD16++ 
R4 – CD14++CD16+ 
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Fig. 3.25 Gene expression profiles of migrated monocytes (MO inside) versus non-migrated 
monocytes (MO outside) and corresponding controls (whole blood monocytes). GeneSpring 
representation of two individual experiments showed no significant difference in gene 
expression between MO outside and controls. Gene expression of migrated MO (=MO inside) 
significantly differs from remaining samples. Colors represent relative expression (red – 
genes higher expressed comparing to controls, green – genes lower expressed comparing to 
controls). 
 
Tab. 3.8 presents 16 chosen genes from 23000 analyzed by assay which should be 
considered for future studies to identify the migrating MO subpopulation. Genes of interest 
were chosen according to their biological function which can influence their migration 
abilities. Products of listed genes are responsible for such a biological processes as cell 
adhesion, cell motility or proteolysis and peptidolysis what indicate that migrated MO  
in deed create specific and not random subpopulation of cells. Expression of showed genes 
in migrated MO is at least 4 time higher than in non-migrated one and control samples. The 
down regulated genes were excluded from further analysis because this result, with high 
probability, is due to fibroblasts contamination. Gene expression has not been verified by 
an independent technique so far. 
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Tab. 3.8 List of up regulated genes analyzed by microarrays in migrated MO versus non-
migrated MO chosen according to their biological function. 
Gene Symbol Gene Name Biological 
Function 
Array Fold 
Change 
Up regulated    
C1R complement component 1,  
r subcomponent 
proteolysis and 
peptidolysis 
5.3 
COL16A1 collagen, type XVI, alpha 1 cell adhesion 4.5 
C1S complement component 1, 
s subcomponent 
proteolysis and 
peptidolysis 
5.0 
CPE carboxypeptidase E proteolysis and 
peptidolysis 
4,9 
HAS1 hyaluronan synthase 1 cell adhesion 4.6 
ISLR immunoglobulin superfamily 
containing leucine-rich repeat 
cell adhesion 4.4 
DDR2 discoidin domain receptor 
family, member 2 
cell adhesion, 
proteolysis and 
peptidolysis 
6.0 
FAP fibroblast activation protein, 
alpha 
proteolysis and 
peptidolysis 
4.6 
CPZ carboxypeptidase Z proteolysis and 
peptidolysis 
4.3 
DCBLD2 discoidin, CUB and LCCL 
domain containing 2 
cell adhesion 4.0 
LAMB1 laminin, beta 1 cell adhesion 4.2 
SRPX sushi-repeat-containing 
protein, X-linked 
cell adhesion 4.1 
PARVA parvin, alpha cell adhesion 4.7 
POSTN osteoblast specific factor cell adhesion 4.3 
SPOCK sparc/osteonectin, cwcv and 
kazal-like domains 
proteoglycan 
cell motility,  
cell adhesion 
4.3 
COL6A1 collagen, type VI, alpha 1 cell adhesion 5.0 
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4. Discussion 
4.1 Discussion of materials and methods 
4.1.1 Cell lines and primary cells 
A number of established human breast cancer cell lines derived from tumors or metastases 
of individual patients is commercially available. These cell lines show various 
characteristics that may serve as a tool to classify them into highly and poorly differentiated 
or infiltrative breast tumor cells. In the current work, two tumor cell lines were first chosen: 
T47D and BT474. Both cell lines derived from invasive ductal breast cancers, but T47D 
were isolated from pleural effusion while BT474 originated from a solid breast tumor. They 
are similar in terms of differentiation marker expression as E-cadherin, desmoplakin, 
vimetin and others and belong to a group of well-differentiated epithelial cell lines 
(Sommers et al., 1994) known to form quite regular spheroid cultures (Seidl, 2001; Friedrich 
et al., 2007; Friedrich et al., 2009). However, in spite of these common features they differ 
for example in cellular CCL2 secretion and MO infiltration into the respective 3-D cultures 
was also different (see chapter 3.1.2). This observation encouraged to broaden the 
spectrum breast cancer cell lines to be examined in the present study. One more well-
differentiated, epithelial cell line (MCF-7) and two poorly-differentiated cell lines (Hs578T, 
BT549) were chosen because they were shown earlier to express different levels of CCL2 
(Mestdagt et al., 2006). The choice of cell lines allowed to correlate the features of interest 
in this thesis (i) CCL2 expression and (ii) MO migration in 3-D cultures to draw a more 
general conclusions (see chapters 4.2.3). All cell lines investigated in the present study 
were able to create spheroids. However, the respective spheroid cultures differed in their 
density and shapes ranging from the compact, perfectly round BT474 spheroids to less 
dense, irregular MCF-7 spheroid cultures (see Fig. 3.2). 
In addition, primary fibroblasts were used: tumor-derived fibroblasts (called also tumor-
associated fibroblasts – TAF) were of major interest, healthy skin fibroblasts were chosen 
as a control in some experiments. TAF were grown from breast tumor sections. However, 
not all sections were able to initiate fibroblasts culture. Difficulties in using primary fibroblast 
were primarily caused by cell senescence and relative small number of fibroblasts  
in culture. In practice, fibroblasts were frozen with a routine protocol at low passage (1-2) 
and subsequently recultured for experimental set-up. Fibroblasts were then used only for  
3-4 passages to avoid senescence-related artifacts. Accordingly, the available material was 
used up quite quickly. Preparing immortalized fibroblasts could be an approach  
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to overcome this problem in future studies. However, due to transformation process 
associated and required for immortalization, genomic alterations occur that clearly would 
have to be considered. Immortalization can be induced in human diploid fibroblasts by 
transfection with human telomerase reverse transcriptase (hTERT) that catalyze the 
addition of TTAGGG repeats to the telomeres of chromosomes (Bodnar et al., 1998). The 
created immortalized cultures maintain a normal or almost normal phenotype with respect 
to growth regulation, morphology, genome stability (Jiang et al., 1999; Morales et al., 1999). 
Immortalization can also be induced by exposure to biological or physical agents as X-rays 
(Namba et al., 1988) or infection with the simian virus 40 SV40 or its large T antigen (SV40 
LT), but at much lower efficacy. Moreover, immortalization via infection with the SV40  
or SV40 LT was shown earlier to result in an altered morphologic appearance and growth 
regulation of cells (Shay et al., 1993). According to some reports, applying of hTERT  
or mutant SV40 LT alone was not sufficient for immortalization of freshly isolated normal 
adult human mammary fibroblasts. The combination of both genes sufficiently immortalized 
cells. However it also affected genomic stability (O'Hare et al., 2001). Numerous studies 
would thus be required to verify that primary fibroblasts isolated from tumor tissues restore 
their TAF phenotype when immortalized. A systematic study has not been documented 
earlier and it was thus decided to not alter the existing model of TAF spheroids, using 
primary/secondary tumor-derived fibroblasts at low passage, in spite of the technical and 
logistic limitations. 
MO were usually freshly isolated from whole blood and immediately used in migration 
experiments since freezing affected their viability and migration capacity. Because of these 
constraints, the experimental design and reproduction of results in the present thesis was 
extremely challenging. 
4.1.2 Multicellular spheroids as a model for migration studies 
Multicellular spheroids are an appropriate in vitro system for a broad spectrum  
of systematic studies in cancer biology requiring a 3-D structure and pathophysiological 
gradients. Holtfreder and Moscona are considered pioneers in the field of 3-D cell culturing 
as they developed the initial methodology for 3-D culture formation. In the 1970s, 
Sutherland and his group inaugurated multicellular tumor spheroids (MCTS) as an in vitro 
model for systematic studies in the field of radiobiology. Since then, spheroids were used  
in a number of studies on biological mechanisms such as differentiation, regulation  
of proliferation, cell death, invasion, angiogenesis and immune response (Mueller-Klieser, 
2000; Gottfried et al., 2006; Friedrich et al., 2007; Jakobsson et al., 2007). The broad 
application of this culture model is related to its specific features which allow to consider 
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MCTS as intermediates between monolayer culture and in vivo tumor. It has been 
demonstrated that cells in MCTS cultures more closely resemble the in vivo situation 
regarding cell shape and cellular environment than conventional culture systems. 
Monolayer cultures (2-D) of tumor cell lines, in spite of their widespread use for studying 
various molecular processes including cell death and cell proliferation, are not able to 
reflect 3-D organization of mammalian tissue with its 3-D cell-cell and cell-matrix 
interactions. Such interactions may critically affect cell physiology since cells form  
a complex communication network including biochemical and mechanical signals (Santini  
et al., 1999; Santini et al., 2000). This leads to loss of tissue-specific properties in 2-D 
cultures (Griffith and Swartz, 2006; Pampaloni et al., 2007). Cell culturing on plastic 
surfaces (as in monolayers) changes cell morphology, which may affect on cell proliferation 
(Chen et al., 1997), differentiation (Lelievre et al., 1998), migration (Jiang et al., 2005) and 
gene expression (Thomas et al., 2002). Cukierman and his group observed that fibroblasts 
cultured as spheroids moved and divided more quickly compared to these cultured as 
monolayers. Also their shape and interactions with ECM were resembling in more details 
those occurring in vivo (Cukierman et al., 2001). 
Tumorall spheroids, in contrast to conventional suspension or monolayer cultures, reflect 
cellular heterogeneity of solid tumors and were found to be similar to avascular tumor 
nodules or microregions of solid in situ tumors. They posses a well-defined geometry with  
a reproducible concentric arrangements of different cell populations: proliferating, quiescent 
and secondary necrotic cells (Fig.4.1) (Mueller-Klieser, 1997;Kunz-Schughart, 1998; Kunz-
Schughart, 1999, Kunz-Schughart, 2004; Friedrich et al., 2007). 
Spheroids are more or less densely packed reaggregates, since single cell suspensions 
obtained from tissue must again create “aggregates”. In order to create 3-D spheres,  
a culture condition must be provided which guarantees that adhesive forces between cells 
are greater than those for the substrate on which they are plated. There is a number  
of methods for achieving this effect: hanging drop cultures, culture plastic ware with non-
adhesive surfaces, microfabricated microstructures, rotatory bioreactors, surface-modified 
substrates or scaffolds, centrifuge compression of cells or formation of MCS by clonal 
growth, as for example reviewed by (Lin and Chang, 2008). In the current work agarose 
was used to coat tissue culture surfaces and create a non-adhesive surface for culturing 
spheroids in 96-well plates in liquid overlay. 
Despite the superiority to monolayer cultures, 3-D cell cultures, also have some limitations, 
since not all cells can form 3-D spheres under in vitro conditions. Some cell types do not 
aggregate at all or create only odd-shaped aggregates. Spheroid formation is determined 
both by properties of cells and by the cellular microenvironment (Mueller-Klieser, 2000). 
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Fig. 4.1 Schematic illustration of the analogy between multicellular tumor spheroids and 
tumor micromilieu (from Kunz-Schughart, Cell Biol Int,1999, 23: 157-161) 
Breast tumor cell lines differ in their ability to create spheroids. Some of these cell lines 
used in the present study, i.e. T47D, MCF-7 and BT474, create reproducible spheroids, 
with BT474 cells producing the morphological most compact ones but others such as  
MDA-MB231 do not aggregate on non-adherent surfaces (Seidl, 2001). Recently, Ivascu 
and Kubbies identified that spontaneous formation of spheroids in MCF-7, BT474 and T47D 
is mediated by E-catherin. Blocking of this adhesion molecule by inhibitory antibody led to 
the disintegration of the spontaneously formed spheroids. They also showed, that the 
addition of specific ECM compounds at defined concentrations are useful to obtain spheroid 
cultures from tumor cells that do not sufficiently attach to each other to form spheroids per 
se (Ivascu and Kubbies, 2007). Non-tumorigenic fibroblasts, regardless of their, origin 
created compact, ECM rich but non-proliferating spherical aggregates (Seidl, 2001). 
Extending the 3-D culturing model to heterologous cell systems opened new perspectives. 
It enabled co-cultivation of: 1) different therapy-responsive tumor cells (Frenzel et al., 
1995); 2) growing tumor cells with stromal cell types such as endothelial cells (EC), 
fibroblasts or immunocompetent cells (Kunz-Schughart et al., 1998); 3) different non-
tumorigenic host cells e.g. fibroblasts with MO (Kunz-Schughart, 1999) or fibroblasts with 
EC (Kunz-Schughart et al., 2006). Fibroblasts and MO may be initiated together with tumor 
cells and eventually form mixed aggregates. However, a disadvantage of this technique  
is that migration phenomena cannot be monitored. In order to monitor MO migration, as  
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in the present study, spheroids were created and subsequently co-cultured with MO 
suspensions according to (Hauptmann et al., 1993;Konur et al., 1996; Gottfried et al., 2003; 
Silzle et al., 2003). This technique allows to analyze immune cell infiltration of tumor and 
fibroblast spheroids. 
3-D tumor spheroids-MAC co-cultures were first applied by Hauptmann et al (Hauptmann  
et al., 1993) who showed different MAC populations to support tumor proliferation and 
migration. Later on, MO migration and MO-to-MAC maturation processes were studied  
in bladder cancer spheroids (Konur et al., 1996; Konur et al., 1998). Immune modulators 
may, however, be released by both tumor and by tumor stromal cells including fibroblasts. 
According to the urothelial cell line model mentioned, Silzle et al. (Silzle et al., 2003) 
designed an experimental set-up to investigate the interactions between fibroblasts and 
MO. The size of spheroids is important in migration studies, since spheroids exceeding 500 
µm diameter may develop central secondary necrosis due to pathophysiological gradients 
including hypoxia-related processes (Fig.4.1). It was shown, that hypoxia inhibits MO/MAC 
migration and downregulates CCL2 expression, although no causal relation was 
documented (Negus et al., 1998; Grimshaw and Balkwill, 2001). 
In the current work the 3-D fibroblast-MO and breast tumor cell-MO model of co-culturing 
was applied to investigate the role of fibroblast-derived chemokine signaling on the MO 
migration process in a three-dimensional cellular context. 
4.1.3 Employment of siRNA approach in 3-D cell cultures 
The mechanism of RNAi is described in the Methods Section, chapter 2.2.7.5.1 and 
schematically shown in Fig. 2.4. RNAi is an interesting biological tool for knocking down 
gene expression. Functional intermediates in the RNAi pathway, siRNAs, may be 
introduced into cells and cause gene silencing. Diagram 4.2 shows the most frequently 
used methods for siRNA delivery and evaluation of its effect. 
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• Electrophysiological Assays
• Cell Growth Assays
• Differentiation Assays
• Apoptotic Assays
• Norden Blot Analysis
• Branched DNA
• Quantitative RT-PCR
• Western Blot Analysis
• ELISA
• Immunocytochemistry
• Immunohistochemistry
• Immunoprecipitation
• Detection of Co-Transfected Markers
siRNA
DELIVERY DETECTION
• Lipid-Mediated Transfection
• Electroporation
• Microinjection
Functional Assays
mRNA Detection Assays
Protein Detection Assays
 
 
Fig. 4.2 Methods of siRNA delivery and methods suitable for gene silencing detection. 
siRNA used for gene silencing is increasingly used for gene function analysis. The silencing 
effect of siRNA is relatively stable and can persist even up to 10 days (Matuliene and 
Kuriyama, 2002). However, the reducing effect can be influenced by the target transcript, its 
expression level, turnover rate and regulation. siRNA method was proved to be useful  
in understanding the roles of individual genes in various cellular processes such as: cell 
cycle (Harborth et al., 2001) apoptosis (Futami et al., 2002), cell differentiation (Kawasaki  
et al., 2002) or insulin signaling (Usui et al., 2003). There is growing interest in RNAi 
utilization for the treatment of various human diseases since it can be applied for targeting 
disease-related genes or human pathogens (Miller et al., 2003;). The experiments 
described by Banerjea et.al. demonstrate the utility of siRNAs delivered into hematopoietic 
stem cells via lentiviral vectors for future in vivo applications (Banerjea et al., 2003). 
The design and application of siRNA does not require dedicated technical training  
or special equipment as it is the case for gene knockouts performed in mice. Moreover, 
knockout of important genes in mice often generates embryonic lethality. The combination 
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of RNAi methodology with 3-D cultures by employing siRNAs in spheroids seemed to be 
far-reaching because of its supposed simplicity and diversity of potential applications. RNAi 
application in 3-D cultures, however, is not widespread. Only few researcher used this tool 
in the context of cancer research. Ivascu and Kubbies applied siRNA molecules to study 
proteins involved in spheroids formation of different breast cancer cell lines (Ivascu and 
Kubbies, 2007). Similarly, Ditttmer et al. silenced PTHrP (Parathyroid hormone-related 
protein) expressed also in breast tumors and proved its influence on spheroids aggregation 
in the MDA-MB-231 cell line (Dittmer et al., 2008).  
In the present work, siRNAs for CCL2 silencing in TAF were applied. The lipid-mediated 
transfection method was chosen to transfer siRNA either into monolayer cultures 
(subsequently cultured as spheroids) or into cell suspensions directly creating spheroids 
(data not shown). Both approaches failed to work in 3-D TAF cultures, as proved at protein 
level. Although several variants of experimental protocols were tested, the desired effect 
was not achieved. Experimental variations included: different dissociation means, siRNAs 
molecules, transfection means, other fibroblast batches. The effect was unexpected 
because satisfactory transfection results in monolayers were reproducibly obtained (~80% 
down-regulation as compared to control). The use of fluorescently labeled siRNA indicated 
that the transfer of transfected cells from 2-D into spheroid culture did not lead to loss  
of siRNA molecules. The green fluorescent light was still visible 7 days after transfection 
(Fig. 3.15). This shows that siRNA molecules were still in transfected cells. It was, however, 
reported, that siRNAs lacking stabilizing modifications may be degradeted and fluorescent 
tag may still remain intact leading to false positive effects (Dharmacon, 2004).  
A phenomenon that would have to be validated for the present study. 
RNAi acts at the mRNA level and it was thus decided to verify whether loss of regulated 
CCL2 protein expression by siRNA relates to mRNA expression profile. In 2-D cultures 
CCL2 mRNA level was significantly decreased as expected and consistent with down-
regulation at protein level. In 3-D cultures transfected with functional siRNA, relative CCL2 
mRNA level was twice as high as in controls. At protein level no change in CCL2 
expression was observed in 3-D cultures. This unexpected result is hard to explain. Since 
outcomes from two independent experiments were comparable, the occurrence of artifact is 
unlikely. Perhaps a systematic study of posttranscriptional regulation of CCL2 would bring 
the answer. It was proven already herein, that fibroblasts cultured as spheroids differ in 
their properties from cultured monolayer (Cukierman et al., 2001). Hence, the presumption 
that production of CCL2 in 2-D and 3-D cultures differs in terms of molecular regulation, 
cannot be rejected. The discussion is difficult because of lack of comparable research in 
this field. Authors may use other, probably more convenient ways of siRNA delivery that 
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were not tested herein (see schema 4.2). Moreover the technique of 3-D culturing in other 
studies using RNAi technologies differ from the one used in the current thesis (Oishi et al., 
2007; Dittmer et al., 2008; Knight et al., 2008) and finally there are no reports on RNAi 
silencing in fibroblasts. It would thus be interesting to determine if CCL2 can be down-
regulated by siRNA in other 3-D cultures e.g. different tumor cell lines, to evaluate whether 
the phenomenon is cell type or culture dependent. Also it should be tested in extended 
studies if other genes despite CCL2 can be silenced by siRNA  
in fibroblasts, to verify if the lack of silencing effect is gene-specific. This, however, was 
beyond the scope of the present study.  
4.2 Discussion of results 
4.2.1 MO migration into spheroids of different origin 
Experiments performed by Silzle et al. revealed that MO proportion in spheroids of breast 
tumor derived fibroblasts after 40 h of co-culture is significantly higher than in spheroids 
derived from normal skin and breast fibroblasts (Silzle et al., 2003). Based on this report, 
MO migration into TAF 3-D cultures was analyzed and compared with MO migration  
in spheroids of a set of breast tumor cell lines and will be discussed in this chapter. 
A relatively constant subpopulation of whole blood MO, roughly 12-15%, is able to infiltrate 
TAF spheroids as documented by Silzle et al. (Silzle et al., 2003) and verified in the present 
study. However, 40 h co-culture time was the standard procedure established for MO 
migration experiments, according to a 3-D co-culture model of urothelial tumor cell lines and 
MO (Konur et al., 1996). During this time interval, MO were capable of completing their 
migration into TAF or normal fibroblasts spheroids. The exact migration kinetics had not 
been monitored. In present study it could be shown that MO need only 4 h to entirely 
infiltrate TAF spheroids. In contrast, in the established urothelial tumor model (Konur et al., 
1996) 4 h after adding MO, migrating cells were detected only at the periphery of the tumor 
spheroids and the infiltration process was regarded as completed only after 24 h of  
co-culture. However, it should be considered that in the referenced study not the ratio of 
MO to tumor cell in spheroids was determined as analytical endpoint, but the time point 
when MO reached the spheroid center. Indeed, the maximum MO-tumor cell ratio could 
have been reached earlier. In the present study completion of MO migration was defined by 
the highest MO-tumor cell ratio using flow cytometric analysis of dissociated spheroid  
co-cultures. This method allows to more accurately estimate the proportion of MO  
in spheroid co-cultures as opposed to immunohistochemistry. 
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The study of MO migration into breast tumor tissue was performed using five different cell 
lines: Hs578T, T47D, MCF-7, BT549 and BT474, all derived from ductal carcinomas but 
possessing a different invasive potential in vitro. BT549 and Hs578T cell lines are described 
as poorly differentiated and highly invasive in vitro, (>80% determined by chemoinvasion 
assay), while MCF-7, T47D, BT474 cell lines are more differentiated and their invasiveness 
was graded from 0 to 40% (Sommers et al., 1994). It was shown that MO infiltration 
depends on the tumor cell line applied in spheroid co-culture with MO. MO infiltration was 
most pronounced in Hs578T spheroids, T47D and BT549 were intermediate while MCF-7 
and BT474 showed very poor infiltration. The 50% MO fraction in Hs578T co-cultures 
accounted to about 25% of the applied blood MO (see chapter 3.1.2 and Tab. 4.1). The 
increased MO infiltration correlated in most cases (excluding T47D)  with the invasiveness. 
The results are consistent with the observation that high MO/MAC content in solid tumors is 
a unfavourable prognostic marker A high MAC index in human ductal breast carcinomas, 
for example, has been shown to correlate with poor prognosis and reduced survival of 
patients (Leek et al., 1996;Goede et al., 1999;Bingle et al., 2002). Moreover, TAM 
infiltration was found to positively correlate with breast tumor cell proliferation as 
determined via Ki67 (MIB-1) immunoreactivity (Tsutsui et al., 2005). However, as already 
mentioned, the outcomes achieved for T47D cell line does not match this hypothesis. T47D 
spheroids are intermediate infiltrated by MO although in vitro invasiveness of this cell line is 
week. MO infiltration is a complex process driven by chemokines and possibly other 
attractants that induces cell adhesion and locomotion (Luster, 1998), hence cell line 
invasiveness can only be one of cell feature important for MO infiltration. 
Since Hs578T tumor cells were the only to show a high rate of infiltration by blood MO  
in spheroid co-culture, even higher than TAF (see Tab. 4.1), this breast tumor cell line was 
chosen for extended mechanistic studies. The subpopulation of infiltrated MO cannot be 
considered as identical to the one infiltrating TAF spheroids. They differ for example in time 
required to complete infiltration of Hs578T spheroids. MO clearly need longer then 4 h 
(which is a sufficient period of time in TAF spheroids) to complete the migration process  
in this tumor spheroid type. An additional discrepancy was shown when blocking the MO 
migration associated chemokine receptor CCR2A/B which will be discussed to some detail 
in chapter 4.2.2.3. 
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4.2.2 CCL2 and cancer 
4.2.2.1 Multifaced role of CCL2 in cancer 
The role of CCL2 in cancer is controversial. It is likely that its effect on cancer  
is multifaceted depending on the particular setting in which it is expressed. CCL2 has been 
shown to display an antitumoral effect in several different models. In at least a few models, 
CCL2 stimulated host anti-tumor responses in a T-lymphocyte-independent manner (Rollins 
and Sunday, 1991). Another consequence of CCL2 activity can be enhancement  
of mononuclear cells to tumor antigen uptake or presentation (T-lymphocyte-dependent 
response) (Manome et al., 1995). However, it is also likely that CCL2 primarily contributes 
to tumor growth and progression considering the fact that CCL2 is expressed by a variety  
of tumor types. Indeed, many tumor entities, including breast cancer are characterized by 
massive mononuclear cell infiltration (Yu and Rak, 2003; Daly and Rollins, 2003). A high 
macrophage content in ovarian, gastric esophageal and ductal breast carcinomas 
correlated with poor prognosis and clinical outcome (Visscher et al., 1995; Leek et al., 
1996; Goede et al., 1999; Bingle et al., 2002; Hagemann et al., 2006) and CCL2, which is 
known as a stimulator of mononuclear cell migration, was demonstrated as a factor that 
facilitates tumor growth and dissemination (Nakashima et al., 1995; Ueno et al., 2000; 
Salcedo et al., 2000; Saji et al., 2001). Furthermore, a study performed by M. Mestdagt  
et al. demonstrated a few years ago a transactivation of the CCL2 promoter following 
activation of the ß-catenin/TCF pathway in breast cancer cell lines and showed that CCL2 
is selectively expressed in breast tumor cell lines known as highly invasive in vitro 
(Mestdagt et al., 2006). However, CCL2 can be produced by many cell types and 
meanwhile has also been detected in TAM, indicating the presence of an amplification loop 
(Balkwill, 2004). In general, tumor-derived CCL2 may contribute to carcinoma progression 
directly or indirectly. CCL2 may act directly on tumor cells, by stimulating themselves  
or neighboring cells (stroma or endothelium) to secrete CCL2. Indirect action may involve 
recruitment of leukocytes that provide growth and antiapoptotic signals, or that provide 
angiogenic signals to tumor cells (reviewed in: (Conti and Rollins, 2004). 
4.2.2.2 The role of CCL2 in MO migration into fibroblasts spheroids 
In many solid tumors, including invasive ductal breast cancer, the MO infiltrate correlates 
with high expression of CCL2 (Mantovani, 1994; Amann et al., 1998; Saji et al., 2001; Silzle 
et al., 2003). High spontaneous secretion of CCL2 in breast tumor derived fibroblasts  
in vitro, indicates some relevance of this chemokine for MO migration into fibroblastic areas 
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in tumors. Data from our laboratory published by Silzle et al. showed that CCL2 
neutralization with specific antibodies was effective in a Boyden chamber assay as  
it decreased the migration of MO towards fibroblast conditioned media (Fig. 4.3.a). 
However, the addition of the same CCL2 neutralizing antibody to the external milieu of TAF 
spheroids, even at a higher concentration, had no effect on MO migration (Fig. 4.3.b). 
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Fig. 4.3 (a) Neutralization of CCL2 in conditioned medium of TAF spheroids PF27 and PF32  
reduced the migratory activity of MO in the Boyden chamber assay. (b) Incubation of 
fibroblast spheroids with CCL2 neutralizing antibody did not reduce MO infiltration. The 
proportion of MO in fibroblast spheroid co-cultures was 40-50% as verified by flow cytometry 
after dissociation and staining independent of the absence or presence (see dot plot diagram) 
of CCL2 blocking Ab. (Silzle et al., Eur. J. Immunol. 2003, 33: 1311-1320) 
Reasons for lack of antibody efficacy in TAF spheroids may be that (i) CCL2 is accumulated 
inside TAF spheroids and in reality its level is much higher than measured in conditioned 
medium, (ii) antibodies cannot sufficiently penetrate the compact spheroid, or (iii) CCL2  
is not a relevant factor for MO migration into spheroid. It is worth to mention that in the 
meantime another group used an antibody approach to neutralize CCL2 in 3-D cell culture. 
Here, neutralization of CCL2 resulted in an almost complete absence of MO migration into 
MCTS (Spoettl et al., 2006). However, not only the Ab was applied three times, starting  
at the point of cell inoculation in liquid overlay but also the spheroid culturing strategy 
differed from the approach used herein. Spoettl et al. initiated mixed spheroids, i.e. they 
seeded tumor cells together with MO in the presence or absence of CCL2 neutralizing Ab.  
It is, however, claimed that the preculture of spheroids and addition of immune cells as 
suspension to an existing 3-D culture should better reflect the in vivo situation of immune  
Discussion  94 
 
cell migration. An approach according to Spoettl et al. was thus not considered for the  
present thesis. 
To answer the questions raised for the spheroid model used herein, several experiments 
were designed. First it was investigated if decreasing the levels of para/autocrine factors 
including CCL2 by replacing supernatant affects MO migration into TAF spheroids. Along 
the experiment, the CCL2 levels in extracellular milieu were monitored. The supernatant 
replacement led to time-delay in MO migration into TAF spheroids. The most prominent 
difference, compared to controls, was observed after 4 and 6 h of co-culturing. At these 
time points CCL2 levels were lower by about 70% and 82% respectively, compared to 
control levels. After 20 h incubation the CCL2 level had almost reached the control level. 
The results indicate that paracrine factors may indeed be responsible for the increased 
migration of MO into TAF as compared with normal fibroblasts. In spite of the observations 
by Silzle et al., who could not block MO migration into TAF spheroids by exposure to a 
CCL2 blocking antibody (Fig. 4.3). CCL2 as one of the paracrine factors reduced by wash-
out experiments cannot be excluded as a factor responsible for MO migration. This 
hypothesis is supported by literature data. Nakagawa et al. studied metastatic colon 
cancers which are also characterized by high MO infiltration rates. They performed 
microarray expression analyses of cancer-associated stromal fibroblast and showed their 
expression profile differed from skin fibroblasts. One of the genes that were significantly up 
regulated was CCL2, another one was IL-6 (Nakagawa et al., 2004). Interestingly, both IL-6 
and CCL2 proteins had been described in our laboratory to be released with a high rate 
from breast tumor-derived as compared with normal fibroblasts (Silzle et al., 2003). Here,  
it was also shown that IL-6 induces CCL2 production in an autocrine loop. 
From experiments performed by Youngs et al. with using a Boyden chamber assay it is 
known that cell migration increases with increasing chemokine levels only up to certain 
concentrations. After exceeding this border-concentration, the migration is reduced. 
Moreover, this study showed that chemokine migratory responses rely at least in part on 
the presence of concentration gradients (Youngs et al., 1997). 
In the current study, only the level of CCL2 measured in supernatant is known, the 
concentration of chemokine inside the spheroid and a potential chemokine gradient are 
unknown and cannot be determined by any simple method. It is, however, expected that 
MO should migrate towards a rising CCL2 concentration. Therefore, we hypothesized that, 
if CCL2 gradient occurs and is important for MO migration, changing or abolishing the 
gradient may decrease MO infiltration into spheroids. Addition of recombinant CCL2 to TAF 
supernatant at 0.02 µg/ml and 0.2 µg/ml (to abolish or change CCL2 gradient) decreased  
to 50% or completely abolished MO infiltration into TAF, respectively. An analogical 
Discussion  95 
 
experiment was performed with normal skin fibroblasts (VF1) spheroids, but here the 
change in CCL2 gradient had no effect on the basic MO migration (see chapter 3.2.2.2). 
Those results strongly support our hypothesis that CCL2 is important for MO migration into 
TAF spheroids and is not relevant for the basic process of MO migration into normal 
fibroblast spheroids. The relevance of stromal-cell derived CCL2 is also supported by  
a recent study performed by Fujimoto et al. They used five different breast cancer cell lines 
as xenograft model in SCID mice. Macrophage infiltration, angiogenic activity and tumor 
growth were recorded in parallel to the determination of various chemoattractants on the 
RNA level in human tumor cells versus mouse stromal cells. Stromal but not tumor cell 
CCL2 mRNA expression was shown to positively correlate with macrophage index. The 
authors also compared CCL2 immunohistochemical staining and macrophage infiltration 
with the clinicopathological data in 128 specimen of human breast cancer and found 
stromal CCL2 as an independent prognostic factor after tumor size and nodal status 
(Fujimoto et al., 2009). 
Based on literature data, other factors modulating MO migration into TAF spheroids and 
fibroblastic stromal areas in tumor, respectively, may include: BRAK (Kurth et al., 2001), 
RANTES (Azenshtein et al., 2002) or VEGF (Valkovic et al., 2005) which will be further 
discussed in chapter 4.2.2.3. Previous studies also indicate that the interaction between 
tumor cells, MO/MAC, fibroblasts and CCL2 is reciprocal. CCL2 might be involved in the 
fibrotic process by inducing fibroblasts to produce collagen via a TGF-β (Ernst et al., 1994). 
The study of Sakai et al. confirms this hypothesis and suggests that peripheral  
CD14-positive MO are directly involved in fibrogenesis through the production of collagen 
type I via autocrine/paracrine production of CCL2 and TGF-β1 through a CCL2/CCR2-
dependent amplification loop (Sakai et al., 2006). 
From the observations in the present thesis, it can be concluded that (i) CCL2 is likely to 
play a critical role in MO migration into TAF spheroids and CCL2 may thus be a central 
factor in MO migration into fibroblastic areas and their local persistence; (ii) Neutralizing Ab 
probably was not able to penetrate created spheroids or to sufficiently block CCL2 within 
the TAF spheroids; (iii) Presumably CCL2 concentration inside the TAF spheroids is higher 
than in the external environment and abrogation of the CCL2 gradient diminished MO 
infiltration. The results provided by the performed experiments on the role of CCL2 in MO 
migration were thus incentive to get deeper insight into the phenomenon of MO migration  
in breast tumor tissue. 
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4.2.2.3 The relevance of chemokine receptors for MO migration into fibroblastic 
tumor areas 
As mentioned earlier, chemokines other than CCL2 and their receptors can be involved  
in MO migration (e.g. BRAK, RANTES. All chemokins activate their pathways by binding to 
7-transmembrane spanning G-protein-coupled receptors which are generally, but not 
exclusively, coupled to pertussis toxin-sensitive Gαi proteins (Amatruda, III et al., 1993; 
Bokoch, 1995). The application of PTX should block Gαi protein-mediated signaling. 
Reduced or abrogated migration of MO into TAF spheroids following PTX exposure would 
thus indicate chemokine receptor signaling to be relevant for increased MO migration  
as compare to normal fibroblasts. The predicted effect was achieved. A range of PTX 
concentrations was used, but all blocked MO migration completely suggesting that MO 
migration into TAF spheroids require chemokine/chemokine-receptor binding and signaling. 
The proportion of MO in TAF-MO co-cultures after exposure to PTX as detected by flow 
cytometry after dissociation is 2-3% which is in a range found in normal (non-tumor-derived) 
fibroblast spheroids. It is unclear whether an imperfect wash-out procedure and MO 
adhered to the spheroid surface may artificially contribute to this basic value of 3% MO  
in co-cultures. PTX B-oligomer which does not posses ADP-ribosyltransferase activity 
(negative control) influenced MO infiltration to some extend at the highest concentration. 
Blocking effect noticed for high concentration of PTX B-oligomer have been shown and is 
explained by other authors, through its contamination with holotoxin (<1%), as reported by 
the supplier (Whitman et al., 2000). However, this contamination should not inhibit migration 
to the degree observed in experiment (about 60% smaller MO ratio for PTX B-oligimer-
treated sample in compare to untreated control sample). Another explanation could be,  
as described by Alfano et al., an inhibitory effect of B-oligomer on CCR5-dependent 
signaling. CCR5 is a receptor for example for MIP-1α (CCL3), RANTES (CCL5) and MCP-2 
(CCL8) and one of main function of this receptor is related to MO migration. Incubation with 
B-oligomer resulted in desensitization of CCR5 and loss of signaling activity associated with 
binding of the natural CCR5 ligands (Alfano et al., 1999). Blocking of this signaling pathway 
can also result in altered MO migration. 
The ligand for CCR5 - CCL5 is increasingly recognized in the literature in the context  
of inflammation and promalignancy. Similar to CCL2, CCL5 is minimally expressed by 
normal breast epithelial duct cells but may be highly expressed by breast tumor cells. 
Moreover, it is also produced by stromal cells in the tumor microenvironment, including 
immune cells, and may affect MO migration via paracrine and autocrine pathways 
(Azenshtein et al., 2002; Soria and Ben-Baruch, 2008). O’Boyle et al. performed 
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chemotactic experiments for members of the MCPs family. They showed that ChTX could 
selectively inhibit MCP-2 (CCL8)-mediated chemotaxis, whereas it did not affect MCP-1 
(CCL2), MCP-3 (CCL7) and MCP-4 (CCL13)-mediated migrations. PTX pre-treatment, 
however, abolished the migration mediated by each of the four MCPs (O'Boyle et al., 2007). 
Analogical experiment was performed using ChTX. Cholera toxin is a specific activator  
of Gαs protein and its application can answer the question if signaling pathways 
independent from Gαi/o take part in the process of MO migration into TAF spheroids (Stryer 
and Bourne, 1986; Neer and Clapham, 1988) The ChTX at a concentration of 1 ng/ml had 
no effect but concentrations of 10 and 50 ng/ml decreased MO migration into TAF to about 
30 to 50%. Since ChTX affected MO migration into TAF spheroids an impact of CCL8 may 
be considered. However, some experiments documented in the literature where PTX and 
ChTX toxins were used, suggested that different signaling pathways mediated by CCL2 
may be under the control of different G-proteins and the response to PTX and ChTX may 
thus both relate to CCL2 signaling (Cambien et al., 2001). CCR2 exists in the plasma 
membrane as a monomer and upon activation by ligand binding it homodimerized. 
Homodimerization in turn leads to G-protein coupling to receptor implicating the possible 
involvement of various signal transduction pathways (Bokoch, 1995). Thus, amongst 
others, CCL2 induces a PTX sensitive rise of intracellular calcium (Sozzani et al., 1993) but 
it also triggers signaling through tyrosine phosphorylation of the receptor and activation  
of the JAK2/STAT3 pathway in a PTX-independent manner. However, the toxin blocks 
JAK2 kinase dissociation from the receptor (Mellado et al., 1998). The understanding  
of signaling pathways triggered by chemokines, however, is even more complex due to the 
revealing possibility of chemokine receptor heterodimerization. Rodriguez-Frade et al. 
observed the formation of CCR2-CCR5 heterodimers induced by simultaneous presence  
of CCL2 and CCL5. The heterodimeric receptor complex showed unique features and 
seems to activate biochemical pathways different from those triggered by homodimers 
(Rodriguez-Frade et al., 2001). 
Two variants for CCR2 receptor exist but their biological significance is not clear. The 
isoforms are alternatively spliced variants of a single receptor gene that differ only in the 
sequence of the cytosolic carboxyl-terminal tail. Due to a shorter amino acid sequence  
in the carboxyl tail, CCR2A does not well traffic to cell surfaces and cannot be detected on 
the MO cell surface at greater than 10% of the level of CCR2B. Outcomes from this study 
also indicate that the CCR2A receptor variant binds CCL2 with high affinity, when 
expressed on the cell surface and is a functional receptor (Wong et al., 1997). The 
experiments with transfected Jurkat T cells revealed differences between the two isoforms 
in terms of Ca2+ flux induction. In CCR2B transfectants, CCL2 induced transient Ca2+ flux 
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was partially sensitive to PTX. In CCR2A transfectants CCL2 did not induce Ca2+ flux 
(Sanders et al., 2000). These observations indicate functional differences between the two 
receptors. It would be interesting to determine the role of different CCR2 isoform in MO 
migration. Since there are no specific blocking agents available that distinguish between 
CCR2A and B isoforms, other experimental approaches e.g. knock-out experiments have to 
be design to study their function. 
Applying of the toxins in the 3-D co-culture model used in the present study, suggests that 
MO migration into TAF spheroids is chemokine dependent. To selectively investigate the 
involvement of CCR2A/B signaling, a CCR2A/B specific antibody was applied. This 
antibody (DOC-3) specifically binds both CCR2 isoforms and block CCL2 signaling (Biber  
et al., 2003; Mahad et al., 2006). CCR2 blockade decreased MO migration into TAF 
spheroids to basal levels according to normal fibroblasts spheroids. Analogue experiments 
with CD11b antibody did not affect MO migratory activity. CD11b together with CD18  
is called Macrophage-1-integrin (MAC-1) or complement receptor 3 (CR3). It binds to C3b 
and C4b, is present on leukocytes including MO, but is irrelevant for MO migration. This 
results provide clear evidence that CCL2/CCR2 signaling is required for enhanced MO 
migration into TAF spheroids. These finding is consistent with literature, where CCR2 
deletion or down-regulation on MO/MAC resulted in absence of cell migration towards 
CCL2 (Sica et al., 2000). 
In summary, CCL2/CCR2 signaling is mandatory for the massive infiltration of spheroids 
from tumor-derived fibroblast, but an impact of other cytokines cannot be excluded so far. 
Chemokines to be considered for extended future studies include for example CCL2, CCL8 
and CCL3 with their receptors. 
4.2.3 CCL2 level and MO infiltration in breast tumor cell line spheroids 
MO migration and its correlation with CCL2 expression was also evaluated for the breast 
cancer cell lines chosen for the present work (Hs578T, BT549, T47D, BT474, MCF-7). 
Since the amount of tumor cells used for inoculation of spheroids and after co-culture with 
MO differed between the cell lines, the number of migrated MO was also calculated as 
percent of total blood MO applied. The Hs578T cell line showed both highest levels  
of cellular CCL2 production and MO infiltration, while lines which expressed very little or no 
CCL2 (MCF-7, BT474) were poorly infiltrated. A correlation between cellular CCL2 release 
and MO migration was thus hypothesized and lines regression analysis was thus performed 
a basis for discussion (see Fig. 4.4). The significance level of 0.05 is just not reached 
probably because of poor number of values. Poor correlation was primarily due to the fact 
that BT549 cells expressed relatively high level of CCL2 but were infiltrated by MO to  
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a lesser extent than T47D spheroids with showed a lower cellular release of CCL2 into the 
supernatant (see Tab. 4.1 and Fig. 4.4).This indicates that MO migration into tumor cell 
areas is more complex and does not exclusively depend on cellular CCL2 production,  
in spite of the fact that cellular release rates calculated from the CCL2 level in supernatant 
may not reflect a potential discrepancy in intraspheroidal CCL2 accumulation and 
development of a gradient. 
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Fig. 4.4 Correlation of cellular CCL2 release (pg/cell in 96 h) of various breast tumor cell types 
in spheroid culture with the infiltration of blood monocytes. y= ax+b. 
Correlation coefficient: r=0.88 
Significance level: p=0.0509 
A study performed by Lu et al. for prostate cancer cell lines showed that CCL2 expression 
positively correlated with cell lines invasiveness. The malignant prostate cell lines 
expressed significantly more CCL2 as compared to non-neoplastic prostate epithelia. 
Moreover, the high expression correlated positively with an advanced pathological state (Lu 
et al., 2006). 
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Tab.4.1 Comparison of cell line characteristics of breast tumor cell lines related to MO 
migration and CCL2 secretion 
Breast 
tumor cell 
line 
Invasiveness* Amount of 
MO 
in spheroid 
(%) 
Migrating 
blood MO 
subpopulation 
(%) 
CCL2 
secretion 
(pg/cell) 
CCL2 
secretion 
(pg/ml) 
Hs578T +++ 48.3 25.9 0.0507 716 
BT549 +++ 8.4 2.7 0.0210 337 
T47D + 18.6 8.9 0.0034 57 
MCF-7 + 3.8 1.1 0 0 
BT474 + 1.3 0.6 0.0002 3 
* activity in Boyden chamber chemoinvasion assay, graded as percent of MDA-MB-231 
activity. + 0-40%, ++ 40-80%, +++ >80% (after Sommers et al., Breast Cancer Research and 
Treatment 1994, 31: 325-335). 
To role of CCL2/CCR2 signaling on MO migration into Hs578T spheroids was directly 
tested via blocking the CCR2 receptors on MO using the DOC-3 antibody (analogically to 
experiments performed for TAF spheroids, see chapter 3.2.4.2). Interestingly, MO  
pre-incubation with DOC-3 antibody, did not affect MO infiltration of Hs578T breast tumor 
spheroids. This was revealed in three independent experiments, i.e. for MO from three 
different donors. The data indicate that factors influencing MO migration are cell line/cell 
type dependent and CCL2 is relevant for MO migration into TAF but not into Hs578T 
spheroids. This hypothesis is also supported by the observation that although TAF express 
higher levels of CCL2 (0.1-0.75 pg/cell) than Hs578T (0.05 pg/cell) MO infiltration is higher 
into Hs578T spheroids than into TAF spheroids, 26% and 16% respectively. As already 
discussed (see chapter 4.2.1) differences in kinetics of MO migration into TAF and Hs578T 
spheroids, confirm this hypothesis. 
The analysis of MO migration into breast tumor cell lines, clearly shows that MO 
subpopulations infiltrating particular cell lines differ in size indicating that they cannot be 
considered as one and the same population. However, this hypothesis of subpopulations  
of MO with different infiltrative potential should be more deeply studied in order to describe 
these differences in details. 
Macrophages isolated from tumor tissues may show a reduced response to CCL2 due to  
a “defective” expression of its receptor (Muller et al., 1997; Sica et al., 2000). In the 
experiment of the present thesis, MO were exposed for a maximum of 40 h to factors 
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secreted by tumor cells and an impact on expression of the receptor cannot be excluded 
since a significant decrease of receptor expression can occur in a very short time. In vitro 
treatment of macrophages with potent endotoxins such as LPS resulted in a dramatic 
decrease of the ccr2 mRNA levels in only 2 h after LPS addition. It is unclear, however, how 
long it takes, until this change mRNA expression transfer to the protein level as this 
depends on translation processes and receptor turnover (Zhou et al., 1999). 
The current study and several other studies (Goede et al., 1999; Ueno et al., 2000; Salcedo 
et al., 2000) focused on CCL2 as a protein that affects the recruitment of MO into breast 
tumor sites. However, as already mentioned, CCL2 is only one of several chemokines 
which are able to attract MO. In addition to CCL2, CCL5, another inflammatory chemokine 
which also possess potent monocyte-recruiting activity, attracted major alteration.  
A preliminary study provided data on constitutive expression of CCL5 by T47D and MCF-7 
cells in vitro (Luboshits et al., 1999). Additionally, it was demonstrated that CCL5  
is over expressed by tumor cells including breast and ovarian cancer (Negus et al., 1997; 
Soria and Ben-Baruch, 2008). Research on the expression of CCL5 and other chemokines 
by all five breast cell lines and MO migration mechanism into spheroids will thus shed more 
light into this phenomenon and will be required to verify which alternative or additional 
paracrine/autocrine modulators are of major relevance. Latest studies on this subject 
showed that from several chemokines implicated in MO migration, only IL-8 was 
spontaneously secreted by the Hs578T spheroid cultures (Kunz-Schughart – personal 
communication). IL-8 activates multiple intracellular signaling pathways downstream of two 
cell-surface, G protein-coupled receptors (CXCR1 and CXCR2) and was recently described 
to enhance MO migration (Gouwy et al., 2008; Waugh and Wilson, 2008). 
4.2.4 Migrating MO subpopulation 
Tumor associated macrophages derive from blood MO, migrate into tumor tissue and 
undergo a process of differentiation determined by the tumor microenvironment. Recruited 
TAM have the potential to dramatically affect tumor development and progression. Since 
peripheral blood MO are the precursors of most tissue macrophages and also of TAM, the 
ability of MO to migrate is essential for their accumulation within the fibroblastic stroma 
surrounding tumor cell islets as shown in invasive ductal breast tumors (Mueller, 1992). 
One of the aims of this thesis was to identify and characterize the migrating blood MO 
subpopulation capable of infiltrating TAF spheroids. Subpopulations of blood monocytes 
can be identified for example by surface antigens. First, we tested if the migrating MO 
subpopulation differ in CCR2A/B expression. DOC-3 antibody staining did not reveal any 
difference between migrating and non-migrating MO, which seems contradictory to the 
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results presented by Mizuno et al (Mizuno et al., 2005). They simultaneously stained MO 
with anti-CD14, anti-CD16 and anti-CCR2 antibodies. This allowed to clearly distinguish two 
subpopulations of MO from which CD14lowCD16high expressed little CCR2, whereas 
CD14highCD16low cells expressed high level of CCR2. Ziegler-Heitbrock and coworkers 
described, in addition to classical CD14++CD16- MO, population of MO, which co express 
CD16 and low level of CD14 (CD14+CD16+). This subpopulation was described as 
proinflommatory because of its higher expression of proinflammatory cytokines and higher 
potency in antigen presentation. This subpopulations differs in expression of cell surface 
molecules including CCR2 which was not detected on CD14+CD16+ MO and highly 
expressed on CD14++CD16- MO (Ziegler-Heitbrock, 2007). The difference may result from 
accuracy of staining or from the preparation of blood monocytes, in current thesis, for this 
step of research, simple one-color staining was employed. 
Human blood MO can be analyzed using flow cytometry by employing multi-color 
immunofluorescence with antibodies directed against CD14 and CD16 antigens. Based on 
CD14 and CD16 expression four fractions were distinguished (CD14++CD16-, 
CD14+CD16++, CD14++CD16++, CD14++CD16+) although there are basically two to three 
populations described in the literature (Ziegler-Heitbrock, 1996; Ziegler-Heitbrock, 2007). 
The fractions were sorted by FACS and their migration activity was compared. None of the 
MO subpopulations significantly differed in the infiltrating potential into TAF spheroids. It is 
particularly interesting when comparing to already mentioned results of Ziegler-Heitbrock 
presenting differences of CCR2 expression in MO subpopulations. Anacuta et al. showed 
that CD14+CD16+ MO (which lack CCR2 and thus not respond to CCL2), migrate in 
response to CX3CL1 and CXCL12 (Anacuta et al., 2003). 
Since integrines play a role in cell adhesion and motility (Weerasinghe et al., 1998; Mouse  
et al., 2001) and therefore may have an impact on migration processes, blood MO were 
analyzed for differences in integrin expression. Integrines LFA-1 (CD11a), MAC-1 (CD11b) 
and VLA5 (CD49e) and their expression on MO, were taken under consideration. Multicolor 
stainings (CD14, CD49e, CD11a and CD14, CD49e, CD11b) did not indicate any 
subpopulation with discrete expression profile with respect to these surface antigens.  
It became clear that looking at random into molecules which could be theoretically involved 
in migration/adhesion mechanisms in cells of interest is not effective. Therefore, multigene 
screening of migrating versus non-migrating MO was performed. This experiment revealed 
a number of genes that is supposedly up-regulated in migrated MO compared to non-
migrated and control ones. Among them, genes associated with cell adhesion, proteolysis, 
peptidolysis or cell motility were present. This experiment could be considered only as  
an introduction into complex analyses. Additional molecular studies like RT-PCR validation 
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of genes should be performed to further evaluate the identified up-regulated genes. Also, it 
has to be considered that the initial experimental set-up did not allow to discriminate 
between genes that differ in the migrating MO subpopulation before or as a result of the 
infiltration process. 
Although a lot of effort has been put into the discovery of migrating MO subpopulation 
based on antigens suggested in the literature, no clear population was distinguished. 
However, the microarray analysis brought promising results that require further evaluation. 
It would be interesting to continue this line of research also because of few reports on this 
subject. In literature, with regard to TAM, mostly reports consider characterization of blood 
MO with respect to different pathological conditions (Finnin et al., 1999; Li et al., 2004; 
Takeyama et al., 2007) not blood MO from healthy donors. Another line of research, 
present in literature is focused on mature macrophages, with expression pattern modulated 
by the specific tissue environment (Konur et al., 1998; Sica et al., 2000). 
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5. Summary 
The majority of invasive-ductal breast tumors develop a desmoplastic reaction. The most 
abundant stromal host cell type in desmoplastic tumors are fibroblasts. In addition to  
tumor-associated/derived fibroblasts (TAF), the complex cellular tumor microenvironment 
comprises other host cell types including endothelial and immunocompetent cells, 
e.g. monocytes (MO) and macrophages (MAC). All of these cells are known to be 
influenced by tumor cells and vice versa have an impact on tumor progression. Invasive 
ductal breast cancer is characterized by a high MO/MAC content. These immune cells are 
predominantly located within the fibroblastic stroma surrounding tumor cell islets.  
The objective of the current thesis was to get insights in the process of MO migration into 
fibroblastic tumor areas. A 3-D spheroid co-culture system in liquid overlay was used as a 
model to resemble the reciprocal interactions between fibroblasts and MO and between 
breast tumor cells and MO. A previous study had shown that TAF 3-D cultures are more 
efficiently infiltrated by blood MO derived from healthy donors as compared to normal skin 
and breast fibroblasts. The fraction of blood MO which infiltrated TAF spheroids ranged 
between 10% and 20% leading to the hypothesis that a particular MO subpopulation may 
show high infiltrative potential into TAF spheroids and fibroblastic tumor areas, respectively. 
Moreover, CCL2 levels were significantly higher in supernatants of TAF as opposed to 
normal fibroblast spheroids indicating that this chemokine may play a role in the process of 
MO migration. However, MO migration into TAF spheroids could not be inhibited by a CCL2 
neutralizing antibody which was highly effective in a Boyden chamber assay.  
In the present work numerous experiments were designed to 
• strengthen the hypothesis that paracrine factors including CCL2 are responsible for 
the increased infiltration of MO into TAF spheroids.  
• identify a potential MO subpopulations in the blood MO pool with enhanced 
infiltrative potential 
• also monitor blood MO infiltration of breast tumor cell line spheroids.  
The data reveal that 3-D spheroid cultures of both fibroblasts and carcinoma cells from 
breast tumor origin are infiltrated by MO. Five different breast tumor cell lines (Hs578T, 
BT549, T47D, MCF-7, BT474) were examined for MO infiltration and CCL2 release. The 
highly invasive Hs578T cell line showed highest levels of cellular CCL2 production and MO 
infiltration, while less invasive MCF-7 and BT474 cell lines, expressing very little or no 
CCL2 were poorly infiltrated. However, the hypothesized correlation between CCL2 
expression and MO infiltration was not confirmed by linear regression analysis.  
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To verify the relevance of paracrine factors, particularly CCL2/CCL2R signaling, for MO 
migration into spheroids of breast tumor origin (especially TAF and highly infiltrated Hs578T 
breast tumor cells) several experimental series were performed. Washing out of paracrine 
factors including CCL2 in TAF spheroids resulted in delayed MO migration. Disruption of 
CCL2 gradient by adding recombinant CCL2 to the external milieu of TAF spheroids, almost 
entirely abrogated the infiltration of TAF spheroids by MO but it does not affect the low, 
basic migration of MO into normal skin fibroblast spheroids. This result indicates that basic 
MO migration may relate to mechanisms different from MO infiltration of TAF spheroids. 
The observation was encouraging to deeper study the paracrine factors signaling in TAF 
spheroids. Experiments to block downstream signaling from Gi/o and Gαs protein coupled 
receptors by pertussis toxin (PTX) and cholera toxin (ChTX), respectively were performed. 
MO recruitment into TAF was inhibited by pre-exposure of MO to PTX and ChTX. However, 
in contrast to PTX, ChTX could not completely block MO migration. The strong inhibitory 
effect of PTX is consistent with described in literature involvement of Gi/o proteins in CCL2 
signaling, however other 7-transmembrane G protein coupled receptors may also be 
affected. Therefore, CCL2 receptor signaling was inhibited by pre-exposure of MO to the 
specific CCR2A/B blocking antibody DOC-3. This approach resulted in an almost complete 
loss of MO infiltration of TAF spheroids. Analogical experiments were performed for 
Hs578T spheroids (chosen because of their high infiltration rate and CCL2 release). Here, 
however, MO infiltration was unaltered by CCR2A/B receptor blockade. This indicates that 
the migration of MO and also the localization of TAM in tumor tissues are affected by the 
individual expression pattern of both stromal and tumor cell compartments. This is 
supported by the additional observation that MO subpopulation size and migration kinetics 
differ in TAF and Hs578T spheroids. Other chemokines implicated in MO migration such as 
CCL5, BRAK, or IL-8 are thus discussed and proposed for extended future studies.  
In order to identify the migrating MO subpopulation, blood MO were stained for surface 
antigens CD14/CD16 that were described earlier to discriminate blood MO populations with 
different infiltrative potential. Staining and flow cytometric analysis allowed to distinguish 
four different MO fractions, however none of these fractions showed differences in 
migration capacity when isolated by fluorescence activated cell sorting and then added to 
TAF spheroids. Because the expression pattern of some other antigens relevant for cell-cell 
interactions did not indicate the presence of a particular subpopulation, the search for the 
blood MO population with high infiltrative potential was extended to a multigene screening 
approach of migrated versus non-migrated MO was performed. It revealed a number of 
genes which seem over expressed in migrated cells and which should be validated and 
further explored in the future.. 
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In summary, CCL2/CCR2A/B signaling was shown to be important for MO infiltration into 
TAF but not Hs578T tumor spheroids. A particular high infiltrative blood MO populations 
according to those described in the literature could not yet be identified. It is concluded that 
paracrine factors from stromal fibroblasts are relevant to govern and/or at least fine tune the 
infiltration and location of blood MO in breast tumor tissue where they supposedly undergo 
abnormal differentiation to become tumor promoting, tumor-associated macrophages. The 
role of fibroblast-derived CCL2 in this scenario has to be emphasized in light of earlier 
evidence that the level of tumor derived CCL2 correlates with the abundance of TAM, poor 
prognosis and clinical outcome in breast tumors.  
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7. Abbreviations 
2-D two-dimensional 
3-D three-dimensional 
α-SMA alpha-Smooth Muscle Actin 
  
Ab antibody 
ADP adenosine triphosphate 
APC allophycocyanin 
  
BRAK Breast and Kidney-expressed Chemokine 
BRCA1 Breast Cancer 1, early onset 
BRCA2 Breast Cancer 2, early onset 
BSA Bovine Serum Albumine 
  
Ca2+ calcium 
cAMP cyclic adenosine monophosphate 
CCL13 (MCP-4) Monocyte Chemoattractant Protein-4 
CCL2 (MCP-1) Monocyte Chemoattractant Protein-1 
CCL7 (MCP-3) Monocyte Chemoattractant Protein-3 
CCL8 (MCP-2) Monocyte Chemoattractant Protein-2 
CCR2 Chemokine (C-C motif) receptor 2 
CD cluster of differentiation 
cDNA complementary DNA 
ChTX Cholera Toxin 
CO2 carbon dioxide 
Cy3  
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Cy5  
  
DAB diaminobenzidine 
DEPC diethylpyrocarbonate 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO dimethylsulfoxid 
DNA deoxyribonucleic acid 
dNTP deoksinucleotide triphosphate 
dsRNA double stranded RNA 
DTT dithiothreitol 
  
ECM  extracellularmatrix 
EDTA ethylenediaminetetraacetic acid 
ELISA Enzyme-Linked ImmunoSorbent Assay 
ER estrogene receptor 
  
F  fibroblasts 
FACS Fluorescent-Activated Cell Sorting 
FCS Fetal Calf Serum 
FcγR Fc gamma Receptor 
FITC  fluorescein 
Fn  fibronectin 
FSC forward scatter 
fw forward 
  
GDP guanosine diphosphate 
GPCR  G protein-coupled receptors 
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GTP guanosine triphosphate 
  
H2O dihydrogen monoxide 
H2O2 hydrogen peroxide 
HRP horseradish peroxidase 
 
 
ICAM-1 Inter-Cellular Adhesion Molecule 1 
IGF-I Insulin-Growth-Factor I 
IGF-II Insulin-Growth-Factor II 
IgG Immunoglobulin G 
IL-1 Interleukin-1 
IL-10 Interleukin-10 
IL-6 Interleukin-6 
ITGA5 Integrin alpha 5 (CD49e) 
ITGAL Integrin alpha L (CD11a) 
ITGAM Integrin alpha M (CD11b) 
  
JAK Janus kinase 
JNK c-Jun N-terminal kinase 
 
 
LFA-1 Lymphocyte Function-associated Antigen 1 
Lkn-1 (CCL15) Leukotactin-1 
LPS lipopolysaccharide 
  
MAC macrophages 
MAC-1 Macrophage-1 antigen 
MAPK Mitogen-activated protein kinase 
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MCS multicellular spheroids 
M-CSF Macrophage Colony-Stimulating Factor 
MCTS multicellular tumor spheroids 
MIP-1α (CCL3) Macrophage Inflammatory Protein-1alpha 
MIP-1β (CCL23) Macrophage Inflammatory Protein-1betha 
MNC mononuclear cells 
MO monocytes 
  
N2 nitrogen 
NA not available 
NK Natural Killer 
nt nucleotide 
  
PBS Phosphate Buffered Saline 
PCR Polymerase Chain Reaction 
PDGF  Platelet-Derived Growth Factor 
PE  R-phycoerythrin 
PR progesterone receptor 
PTX Pertussis Toxin 
  
RANTES (CCL5) Regulated upon Activation, Normal T-cell 
Expressed, and Secreted 
rev reverse 
rhMCP-1 recombinant human MCP-1 
RNA ribonucleic acid 
RNAi RNA interference 
rpm round per minute 
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RPMI Roswell Park Memorial Institute 
RT reverse transcription 
  
SD  standard deviation 
seRNA sense RNA 
siRNA small interfering RNA 
SSC side scatter 
STAT3 signal transducer and activator of 
transcription 3 
  
TAF tumor associated fibroblasts = tumor derived 
fibroblasts 
TAM tumor associated macrophages 
TC Tumor cells 
TGF-β  Tumor Growth Factor beta  
TMB tetramethylbenzidine 
TNF  Tumor Necrosis Factor 
  
VCAM-1 Vascular Cell Adhesion Molecule 1 
VEGF Vascular Endothelial Growth Factor 
VLA-4 Very Late Antigen-4 
VLA5A fibronectin receptor 
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